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ROLES AND REGULATION OF NF-kB IN PLATELET-DERIVED GROWTH
FACTOR TRANSFORMED CELLS

Takeshi Shimamura, Ph. D.
Western Michigan University, 2002

Platelet-derived growth factor (PDGF) is overexpressed in various cancer cells and
the overexpression may be correlated with the prognosis o f several types o f cancers.
Binding o f PDGF to its receptors induces receptor dimerization and subsequent auto
phosphorylation o f tyrosine residues in the receptor’s cytoplasmic domains.

The

phosphorylated tyrosine residues interact with the secondary signaling molecules to
initiate signaling cascades that trigger cellular changes by affecting downstream
effectors.

In our recent publication, we have shown that a NF-icB mediates the

transformation o f mouse fibroblast cells overexpressing PDGF B chain.

Though

there is a significant correlation between PDGF stimulation and N F- k B activity, it is
still unclear what secondary signaling molecules and downstream targets regulate NFkB

activity in the cell.

In the glioblastoma cell line U87-MG which is known to

overexpress the PDGF B chain and the PDGF beta receptor, N F - kB activity is
significantly increased. A dominant negative mutant o f PDGF beta receptor missing
five intracellular tyrosine residues, which is unable to activate multiple secondary
signaling molecules significantly, decreased N F- k B activity when it was introduced
into U87-MG cells. When one o f the five tyrosine residue is added back so that the
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negative PDGF beta receptor can only activate PI3-K pathway, NF-kB activity
returned to the level that was normal for U87-MG the cells.

In addition, treating

U87-MG cells with chemical inhibitors o f the phosphatidylinocitol 3 kinase (PI3-K)
pathway resulted in the significant inhibition o f NF- k B activity in a dose dependent
manner. The use o f short interfering RNA (siRNA) against p i 10 kinase o f PI3-K to
suppress the expression o f p i 10 kinase also resulted in the inhibition o f PI3-K
pathway activity and NF- kB activity. The study presented here demonstrates that the
PI3-K pathway is one o f the pathways that controls NF- kB activity in U87-MG cells.
Elucidating the exact signaling cascades that mediate NF- kB activity upon PDGF
stimulation will unveil a significant mechanism o f PDGF induced transformation,
which may lead to the discovery o f novel molecular targets to suppress tumors with
high PDGF activity.
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INTRODUCTION

According to the American Cancer Society 555,500 Americans are expected
to die from cancer this year which means one out o f every four deaths in the U.S. is
related to cancer. As cancer clearly poses a serious threat to the public health, both
the U.S. government and

America’s pharmaceutical companies are putting

considerable resources and efforts to discover cures for cancer.

In the year 2001

alone, 402 medicines are in different stages o f clinical trials for cancer treatment.
Many medicines are designed to target biological mechanisms induced by
growth factors, as growth factors are known to play essential roles in many human
cancers.

Platelet-derived growth factor (PDGF) is a growth factor involved in a

variety o f normal developmental and physiological processes, but its over-expression
has also been correlated with the development o f several types o f cancers such as
glioblastomas, breast cancers, Wilms tumor, and colon cancer (Bronzert et al., 1987;
De Jong et al., 1998; Hsu et al., 1995; Nister et al., 1991; Rozengurt et al., 1985).
The expression o f PDGF appears to be involved in the actual pathology of the tumor
and not a fortuitous event. A reduction in tumor cell growth and/or a change in tumor
cell morphology has been observed when they are treated by inhibitors o f the PDGF
receptor tyrosine kinase or made to express dominant negative mutants o f the PDGF
receptors and PDGF (Shamah et al., 1993; Strawn et al., 1994; Vassbotn et al., 1994).
Due to the central role that PDGF plays in many tumors, it has become o f increasing

I
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interest to understand what secondary molecules PDGF stimulates to achieve these
undesired results. Although several laboratories have investigated what secondary
signaling molecule might be involved, there have been no studies investigating the
role that NF- kB might play.
Growing evidence suggests that NF-kB and the signaling pathways that are
regulating its activation are important for tumorigenesis (Karin et al., 2002). NF-kB
has been recognized as an inducible transcription factor that targets a specific
sequence o f genes involved in the inflammatory and immune responses (Baeuerle,
1991). NF-kB is a family o f proteins that belongs to reticuloendotheliosis (REL)
family and the discovery that the p50 subunit o f NF-kB shows high homology to an
oncoprotein o f the REL retorovirus (REV-T) (Gilmore, 1999a, 1999b) suggested that
NF-kB might participate in the development o f cancer. Cancer cells generally lose
the ability to control proliferation and the ability to force the cell to the programmed
cell death. NF-kB may play a role in bolt o f these processes as it has been shown to
be involved in cell proliferation by inducing cell cycle protein cyclin D l expression
(Cao et al., 2001; Guttridge et al., 1999; Hinz et al., 1999) and inhibit apoptosis by
upregulating the transcription o f cellular inhibitor o f apoptosis (cLAP), caspase 8 /FAS
associated death domain like IL-ip-converting enzyme inhibitory protein (cFLIP),
and members o f BCL-2 family (Beg & Baltimore, 1996; Karin & Lin, 2002; Liu et
al., 1996; Van Antwerp et al., 1996; C. Y. Wang et al., 1999a; C. Y. Wang et al.,
1999b).

2
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The most well-studied NF-kB is a heterotrimer o f the proteins NFKB1 (p50),
ReLA (p65), and iKBa, which primarily exists in the cytoplasm as inactive complex
(Baeuerle, 1991).

This complex remains in the cytoplasm as the IkB family o f

proteins masks the nuclear localization signal sequence o f the p50/p65 dimer (Ganchi
et al., 1992). Upon an appropriate stimulus, two serine residues on IkBoc become
phosphorylated by one o f several different kinases including IkB kinase p (IKK-P),
followed by its degradation by the 26S proteasome. Dissociation o f IkB from the
complex uncovers the nuclear localization signal sequence o f the p50/p65 dimer and
allows the translocation o f the dimer to the nucleus (Finco & Baldwin, 1995; Rice &
Ernst, 1993).

The p50/p65 dimer binds to its target genes and regulates their

transcriptions.
In our recent publication, we have demonstrated that the activity o f a
transcription factor, NF-kB, was significantly increased in mouse fibroblast cells
transformed with the PDGF-B chain (Shimamura et al., 2002). Acetylsalicylic acid
(ASA) and salicylic acid (SA), which are known to inhibit the dissociation o f a
regulatory protein IkB from NF-kB complex in the cytoplasm, significantly reduced
NF-kB activity and also reduced focus formation in mouse fibroblasts transformed by
the PDGF B chain gene. The inhibition was highly specific, as other non-steroidal
anti-inflammatory drugs (NSAIDs), that do not have an effect on NF-kB activity, did
not affect focus formation. Furthermore, a similar inhibition on NF-kB activity was
observed by the expression o f a dominant negative mutant o f IkBgc that could not be

3
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phosphorylated and hence formed stable complexes with p50/p65, or a mutant o f p65,
p65AC, that lacked the carboxy terminal transactivating domain. The expression o f
either the IicBa mutant or p65AC resulted in a reduction o f NF-icB activity. The
reduction o f NF-icB activity was correlated with the decrease in PDGF B chain
induced transformation in mouse fibroblasts.
Our results demonstrate that a NF-tcB plays a key role in the transformation o f
mouse fibroblast cells by the PDGF B chain, but the signaling mechanisms to
transduce signals from PDGF receptors to NF-kB have not been elucidated in this
system and in glioblastoma cell lines dependent on PDGF B chain stimulation.
In order to determine w hat secondary signaling molecules and downstream
pathways are involved in the signaling between the PDGF P receptors (PDGFPR) and
NF-kB, NF-kB gene reporter assays were performed with the presence o f different
chemical inhibitors of known pathways including PI3-K inhibitors LY294002 and
Wortmannin, a P44/42 Mitogen Activated Protein Kinase (MAPK) inhibitor U 0126,
and a p38 MAPK inhibitor SB203580.

Results have shown that the presence of

phosphatidylinocitol 3 kinase (PI3-K) inhibitors, LY294002 and Wortmannin,
suppressed NF- kB activity in U87-MG cells known to be PDGF B chain dependent
for growth and prognosis. The results suggest that PI3-K pathway is involved in the
regulation o f the NF- kB activity in the U87-MG cells.
Based on the findings, two other experimental approaches were used to test
whether PI3-K pathway is important for controlling N F- kB activity in glioblastoma
cells.

First, RNA interference (RNAi) was used to specifically suppress the
4
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expression o f the pi 10 catalytic subunit o f PI3-K enzyme. Short interference RNAs
(siRNAs) specifically designed to inhibit the catalytic subunit o f the PI3-K. pathway
were used to identify if suppressing the PI3-K pathway would have an effect on NFkB

activity in glioblastoma cells.

Second, dominant negative PDGFpRs that are

unable to trigger the signaling through PI3-K were transfected into the cells to
examine their effects in regulating NF-kB activity.
Identifying signaling cascades responsible for inducing NF- kB activity upon
PDGF stimulation can provide insight to new therapeutic targets for combating
cancers. Therapeutic agents to suppress the signaling cascades from activated PDGF
receptors to the activation o f NF- kB could give a rise to a new array o f therapeutic
agents for cancer treatments as it may suppress proliferation o f cancer cells showing
PDGF dependency. This study presented provides insight into the biology o f PDGFdependent cancer cells and creates practical approaches to develop a highly specific
anti-cancer agent.

5
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REVIEW OF LITERATURE

Platelet-derived Growth Factor and Tumorigenesis

Cancer cells are characterized mainly by their uncontrolled proliferation and
the capability to colonize the body parts composed by normal tissue (Alberts, 1994).
Cancer cells arise from normal cells due to the cumulative alterations in a somatic
cell’s DNA sequence, which can be triggered by many known factors such as
exposure of the host to chemicals, ionizing radiation, and viruses (Alberts, 1994).
According to Hanahan and Weinberg, tumorigenesis entails six critical
alterations to the normal cells (Hanahan & Weinberg, 2000).

These alterations

include self-sufficiency in growth signals, insensitivity to growth inhibition,
avoidance o f apoptosis, immotalization o f the cell, sustained angiogenesis, tissue
invasion, and metastasis.

Platelet-derived Growth Factor (PDGF) fulfills some but

not all o f these. PDGF is a growth factor that can stimulate cell growth by autocrine,
paracrine, and internal autoactivation mechanisms (Bejcek et al., 1989; C. H. Heldin
& Westermark, 1999), which is known to prevent apoptosis. Several different types
o f mutations are responsible for the overexpression o f PDGF and the sustained
stimulation o f cell growth by PDGF can be a critical step in the cellular
transformation leading to tumorigenesis.

Thus, studying the biology o f growth

factors such as PDGF has relevance in providing insight in prevention o f
tumorigenesis and cancer.
6
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Although PDGF is involved in a variety o f normal developmental and
physiological processes, its over-expression has been correlated with the development
o f several types o f cancers such as glioblastomas, breast cancers, Wilms tumor, and
colon cancer (Bronzert et al., 1987; De Jong et al., 1998; Hsu et al., 1995; Nister et
al., 1991; Rozengurt et al., 1985). The expression o f PDGF m ay be involved in the
actual pathology o f the tumor and not an accidental event. PDGF over-expression in
mouse fibroblast NIH3T3 cells results not only in focus formation but also in
increased proliferation rates (Clark et al., 1993; Wahl et al., 1989).

The v-sis

oncogenes in two acutely transforming simian sarcoma virus and feline sarcoma virus
have been identified as identical to the PDGF gene (Devare et al., 1983). Both v-sis
and its cellular counterpart c-sis have been found to transform cells when they are
overexpressed in the cells that express PDGF receptors (Bauer et al., 1985) and the
sis genes cause tumors in animals (C. H. Heldin & Westermark, 1999). By using
inhibitors o f PDGF receptor tyrosine kinase activity or dominant negative mutants o f
the PDGF receptors and PDGF, it has been shown that a reduction in tumor cell
growth and/or a change in tumor cell morphology can be induced (Shamah et al.,
1993; Strawn et al., 1994; Vassbotn et al., 1994).

Platelet-derived Growth Factor

As isolated from platelets, PDGF exists as 30 kDa hetero- or homodimers o f
two structurally related but genetically distinct polypeptides designated A and B
chains (C.-H. Heldin et al., 1989). The A chain is derived from a gene with seven
7
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exons located on chromosome 7 and includes two differentially spliced variants with
125 or 110 amino acid (aa) residues (Betsholtz et al., 1986; Bonthron et al., 1988;
Rorsman et al., 1988). The difference between the long and short forms comes from
the result o f alternative exon usage, with the long form using 18 aa residues from
exon 6 , but none from exon 7, and the short form using 3 aa residues from exon 7, but
not from exon

6

(Bonthron et al., 1988). It is known that the short form is more

abundant in normal cell (Matoskova et al., 1989). The B chain gene consists o f
exons on chromosome

22

6

and is identical to the human c-sis gene, which is also

homologous to the monkey v-sis (simian sarcoma) oncogene (Johnsson et al., 1984).
c-sis encodes for a precursor polypeptides o f 241amino acid residues, which is 27kDa
in size. This precursor is proteolytically processed to a 16 kDa, 160 amino acid
residue polypeptide (Betsholtz et al., 1986; N. E. Heldin et al., 1993), and finally a
12kDa mature polypeptide with 109 amino acid residues (Collins et al., 1987; Collins
et al., 1985; N. E. Heldin et al., 1993; Johnsson et al., 1984; Ostman et al., 1992).
PDGF is a potent mitogen for a variety o f cells in tissue culture and is closely
involved in the process o f tumor development (Bronzert et al., 1987; De Jong et al.,
1998; Hsu et al., 1995; Nister et al., 1991; Rozengurt et al., 1985). A possible Nlinked glycosylation site is known to exist in the mature A chain, but not the B chain
(Betsholtz et al., 1986).
Recently, two new PDGF chains have been described.

Both the C and D

chains are secreted from the cell with a CUB domain in the N-terminus. The CUB
domain contains binding sites for extra cellular matrix molecules and the CUB
8
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domain needs to become cleaved o ff for the C and D chains to be biologically active.
The C chains form homodimers that are expressed at the cell surface as
transmembrane proteins from which a soluble hormone is secreted upon proteolytic
cleavage (X. Li et al., 2000). Although the D chain appears to form soluble secreted
homodimers, these homodimers must also be proteolytically activated (Bergsten et
al., 2001; LaRochelle et al., 2001). In contrast to C and D chains, the A and B chains
are able to form both soluble hetero and homodimers without proteolytic activation
after secretion (C.-H. Heldin et al., 1989; C. H. Heldin & Westermark, 1999).

PDGF Receptors

The effects o f these isoforms are mediated by two different cell surface
receptors, the type a and type P PDGF receptors (PDG FaR and PDGFPR) (Bergsten
et al., 2001; Bywater et al., 1988; Deuel, 1988; C.-H. Heldin et al., 1989; C. H.
Heldin & Westermark, 1999; LaRochelle et al., 2001).

Both receptors are single

polypeptides composed o f an extracellular region with immunoglobulin-like domains,
a single transmembrane region, and an intracellular domain that possesses protein
tyrosine kinase activity (Deuel, 1988; C.-H. Heldin et al., 1989). The type a receptor
is a 170 kD protein consisting o f 1066 amino acids and the type P receptor is a 190
kD protein consisting o f 1074 amino acids.
While the type a receptor can bind to the A, B, and C homodimers and also
the AB heterodimer, the type P receptor exhibits a more restricted binding pattern
being only able to bind to the AB heterodimer and the B and D homodimers (Figure
9
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1) (Bergsten et al., 2001; C.-H. Heldin et al., 1989; LaRochelle et al., 2001; X. Li et
al., 2000). Upon binding o f the appropriate ligands, both receptor types dimerize
which results in auto-phosphorylation o f specific intracellular tyrosine residues by the
receptors’ tyrosine kinase activity (Bergsten et al., 2001; C. H. Heldin & Westermark,
1999; LaRochelle et al., 2001; X. Li et al., 2000). These tyrosine residues on the
receptors serve as docking sites for many proteins through interactions with the src
homology 2 (SH2) domains o f secondary signaling molecules (Arvidsson et al., 1994;
Escobedo et al., 1991a; Escobedo et al., 1991b; Kashishian et al., 1992; Kazlauskas
et al., 1993; Kypta et al., 1990; W. Li et al., 1992; Mori et al., 1993; Ronnstrand et
al., 1992; Yokote et al., 1996).

It has to be noted that homodimeric a a - and PP

receptor complexes trigger different effects in the cells (C. H. Heldin & Westermark,
1999).

10
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PDGFCC

Figure 1.

PDGFDD

Interactions Between PDGF Isoforms and PDGF Receptors.
While PDGF A and B chains are secreted in the biologically active forms,
PDGF C and D chains are secreted as inactive forms that require
proteolytic cleavage in the proximity o f the extracellular matrix. A chain
and B chain can form either homo- or hetero-dimers while C and D chain
can from only homo dimmers, a and P receptors can form either homo- or
hetero- dimers upon ligand (PDGF) binding.

11
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The rat neu gene product NEU has been found to be identical to the epidermal
growth factor receptor (W einer et al., 1989). The receptor tyrosine kinase NEU can
be oncogenic if a single amino acid in the transmembrane domain is mutated
(Bargmann et al., 1986a, 1986b; L. M. Petti et al., 1998; L. M. Petti et al., 1997).
The single amino acid substitution was later found to cause receptor dimerization,
which ultimately caused constitutive receptor tyrosine kinase activity (Smith et al.,
1996; Weiner et al., 1989). A substitution of the insulin transmembrane domain with
the mutant c-NEU transmembrane domain (NEU*) was shown to constitutively
activate the insulin receptor kinases (Yamada et al., 1992). It has been shown that a
chimeric PDGF P receptor including the transmembrane domain o f constitutively
activated NEU (erB-2) not only constitutively phosphorylated the receptor tyrosine
residues but also transformed Ba/F3 cells to growth factor independence and
morohologically transformed mouse C l27 cells (L. Petti et al., 1991) and pl85neu*
transmembrane domain in the PDGFpR has been demonstrated to facilitate receptor
homodimerization,

thus

inducing

tyrosine

autophosphorylation

followed

by

association with important secondary signaling molecules and possible transforming
activity (L. M. Petti et al., 1998).
In addition, naturally occurring chimeric PDGF P receptors have been
identified in chronic myelomonocytic leukemia cells (Golub et al., 1994). In the
chimeric receptors, the cytolasmic and transmembrane domains were fused to the
dimerization domain o f the transcription factor TEL (Golub et al., 1994) or
Huntingtin interacting protein

1

(Ross et al., 1998).

These naturally occurring

12
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chimeric PDGF receptors are shown to constitutively phosphorylated on their tyrosine
residues on

the

intracellular domains

resulting

growth

factor

independent

proliferation o f hematopoietic cells (Carroll et al., 1996; Ross et al., 1998).

Secondary Signaling Molecules and the PDGF Receptor

Several secondary signaling molecules have previously been shown to be
important for PDGF to induce either focus formation or colony formation in soft
agarose. By introducing PDGF receptors that contained multiple point mutations in
tyrosine residues into cells from the Patch mouse that lack PDGF type a receptors, it
was demonstrated that either phosphatidylinositol 3-kinase (PI3-K) or Phospholipase
C y (PLC-y) were sufficient for colony formation (DeMali et al., 1997).

However, it

has also been demonstrated that dominant negative mutants o f both the Ha-ras protein
and protein kinase C5 (PKC5) interfere with the ability o f PDGF to stimulate foci and
soft agar colony formation in NIH3T3 cells (W. Li et al., 1996). Furthermore, the
PK.C8 mutant did not interfere with Ha-ras mediated stimulation o f mitogen activated
protein kinase (M APK) but did inhibit stimulation o f the transcription o f genes that
were responsive to 12-O-Tetradecanoylphorbol 13-acetate (TPA) (W. Li et al., 1996).
Once intracellular tyrosine residues o f PDGF receptors are phosphorylated by
PDGF binding to the receptor, these residues are able to associate with a variety o f
secondary signaling molecules including GRB2 (Arvidsson et al., 1994), GRB7
(Yokote et al., 1996), NCK (W. Li et al., 1992), ras GTPase activating protein
(rasGAP) (Kashishian et al., 1992), phosphatidylinositol 3 kinase (PI3K) (Escobedo
13
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et al., 1991b; Kashishian et al., 1992), members o f the src family (Kypta et al., 1990;
Mori et al., 1993), SHP-2 (Kazlauskas et al., 1993), phospholipase C y(PLCy;
(Ronnstrand et al., 1992)), and receptor-like protein tyrosine phosphatase DEP-1
(Persson et al., 2002). The specific tyrosine residues on PDGF p receptors that have
been reported to associate with the secondary signaling molecules mentioned above
are summarized in both Table 1 and Figure 2. Signaling subsequent to the PDGF
receptor activation is modulated intracellularly through interactions with various
signaling cascades.

14
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Table 1
Secondary Signaling Molecules Associate Tyrosine Residues on PDGF P Receptor

■
GRB2 and GRB7

716/775

Nek

751

Stat5
Stat3
ras GTPase activating protein
(GAP)
phosphatidylinositol 3 kinase
(PI3K)

579/581/775
7

771
740/751

sre family (Src)

579/581

Jak family
Crkll
SHP-2

7

Phospholipase C y (PLCy)

1021/1009

She

579/740/751/771

Fer
DEP-1
APS

7

7

1009/763

1021
1021

(Yokote et al., 1996)
(Schlessinger, 1993)
(Arvidsson et al., 1994)
(W. Li et al., 1992;
Nishimura et al., 1993)
(Novak et al., 1996)
(Y. Z. Wang et al., 2000)
(Kazlauskas et al., 1992)
(Kashishian et al., 1992)
(Escobedo et al., 1991a;
Fantlef al., 1992; Kashishian
et al., 1992; Kazlauskas et
al., 1992)
(Escobedo et al., 1991b)
(Kypta et al., 1990) (Mori et
al., 1993)
(Valgeirsdottir et al., 1998)
(Matsumoto et al., 2000)
(Kazlauskas et al., 1993)
(Klinghoffer & Kazlauskas,
1995)
(Kashishian & Cooper, 1993;
Ronnstrand et al., 1992;
Valius et al., 1993)
(Roche et al., 1996) (Yokote
et al., 1994)
(Kim & Wong, 1995)
(Persson et al., 2002)
(Yokouchi et al., 1999)
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Studies elucidating secondary signaling molecules that associate with PDGF
receptors utilize mutant PDGF receptors whose tyrosine residues are mutated to
different amino acids. It has been shown that mutations in PDGF p receptor tyrosine
residues 740/751/771/1009/1021 (F5Y) inhibited association o f PI-3K, GAP, SHP-2,
and PLC-y to the receptor, which resulted in the inhibition o f PDGF stimulated DNA
synthesis and sphingosine kinase activity (Olivera et al., 1999).

Substitution of

tyrosine residues on the cytoplasmic domain with different amino acids has been used
to identify secondary signaling molecules associating with PDGF receptors. Lysine
residue 634 in PDGF P receptor was substituted with arginine and the mutant receptor
was unable to activate its kinase upon PDGF stimulation (Olivera et al., 1999). In
addition, the F5Y mutant was unable to associate with PLC-y, PI-3K, GAP, and SHP2, and failed to activate sphingosine kinase and DNA transcription upon PDGF
stimulation (Olivera et al., 1999).

In the following sections, signaling pathways

known to be downstream of PDGF p receptors are discussed in detail.

Phospholipase C - v

Phospholipase C - y (PLC-y) is known to associate with tyrosine 1021 and
1009 residues o f active PDGFPR (Kazlauskas et al., 1993; Klinghoffer & Kazlauskas,
1995). PLC-y is known to use Phosphatidylinositol (PtdIns)-4,5-P2 as substrate and
produces inositol-1,4,5 -P3 and diacylglycerol. PLC-y also stimulates the release of
Ca2+ from internal storage to activate protein kinase C (PKC) (Berridge, 1993). It has

17
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been shown that PDGF mediated activation o f PLC-y is not directly responsible for
cell growth or cell motility in most cell types, but PLC-y has been shown to
upregulate cell motility and growth in some cells (Kamat & Carpenter, 1997).

Src

Src is known to bind tyrosine residues 579 and 581 o f active PDGFPR
(Escobedo et al., 1991b; Kypta et al., 1990; Mori et al., 1993). Src family tyrosine
kinases possess a src homology 3 (SH3) domain, a SH2 domain, and a catalytic
center. The association o f the SH2 domain with autophosphorylated PDGF receptor,
dephosphorylation o f C-terminal tyrosine phosphorylation, and phosphorylation o f
other tyrosine residues causes the activation o f Src, which seems to play essential role
in PDGF-mediated mitogenesis (Erpel & Courtneidge, 1995).

Grb 2/Sos 1

Grb2 is an adaptor molecule known to associate with activated PDGFPR
tyrosine residues 716 or 775 via its SH2 domain (Arvidsson et al., 1994;
Schlessinger, 1993; Yokote et al., 1996). Grb2 also contains two SH3 domains that
provide binding sites for a guanidine nucleotide exchange factor Sos known to
activates Ras (Schlessinger, 1993). As Ras has been reported to bind serine/threonine
kinase Raf which activate the mitogen-activated protein kinase (MAPK.) pathway,
Grb2/Sos seems to take a part in PDGF stimulation o f cell growth, migration, and
differentiation (Hu et al., 1995; Rodriguez-Viciana et al., 1994).
18

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fer belongs to the c-Fer and c-Fes family o f tyrosine kinases that contain SH2
domain (C. H. Heldin et al., 1998). C-Fer is known to co-immunoprecipitate with
PDGF p receptor, but its function and regulation have not been elucidated (Kim &
Wong, 1995).

Stat

Stat isoforms have been reported to play roles in cytokine mediated signal
transduction and Stat I, 3, and 5 are known to associate with PDGF P receptor
(Choudhury et al., 1996; Valgeirsdottir et al., 1998; Vignais et al., 1996; Yamamoto
et al., 1996). Upon binding to phosphotyrosine, Stat isoforms have been shown to be
activated and translocated to the nucleus to bind specific target sequences as a homoor hetero- dimers (Novak et al., 1996).

Although the exact role o f how PDGF

activates Stat has not been elucidated, Stat in conjunction with Jak kinases have been
shown to play a role in PDGF-mediated mitogenesis (Novak et al., 1996).

SHP-2

SHP-2 is an universally expressed tyrosine phosphatase and known to bind to
activated PDGFpR phosphotyrosine residues with different affinity. SHP-2 may aid
in PDGF mediated MAPK activation (Shi et al., 1998) and activation o f Ras by
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binding to Grb2 (W. Li et al., 1994), but it has also been shown that SHP-2
expression can suppress the PDGF induced transformation (Jazayeri et al., 2000).

GAP

RasGAP contains two SH2 domains and that binds to phosphorylated tyrosine
771 on PDGF P receptor (Fantl et al., 1992; Kashishian et al., 1992; Kazlauskas et
al., 1992) and it has not been shown to associate with PDGF a receptor (C. H. Heldin
et al., 1998). GAP is a GTPase to activate Ras but its function has not been fully
elucidated.

It has been known that PDGF-mediated Ras activation is much more

efficient in the cells with GAP activity suppressed than normal cell (van der Geer et
al., 1997) and it has been known that expressing PDGF p receptor with several
tyrosine mutations except tyrosine 771 in the cells is known to decrease PDGF
mediated mitogenesis (Valius et al., 1995).

The evidence suggests that PDGF

activated G A P somehow negatively controls PDGF-mediated Ras activation.

Phosphatidyl Inositol 3-Kinase

The PI3-K pathway utilizes phospholipids as secondary signaling molecules
to transduce signals from the periphery o f the cell to the interior o f the cell (Fruman et
al., 1998; Vanhaesebroeck et al., 1997a). The membrane lipid phosphatidylinositol
(Ptdlns) is composed of fatty acids, triglycerides, and a head group with five hydroxyl
groups (Figure 3). The hydroxyl groups are subject to phosphorylation by PI3-K
family o f kinases (Fruman et al., 1998; Vanhaesebroeck et al., 1997a). So far, three
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classes of PI3-K have been identified and classified based on sequence homology and
substrate preference (Domin & Waterfield, 1997).

Class I PI3-K phosphorylates

PtdIns-4,5-bisphosphate in vivo and also phosphrylate PtdIns-4-P in vitro (Rameh el
al., 1997a; Rameh et al., 1997b; Zhang et al., 1997). Class II PI3-K is known to
phosphorylate Ptdlns and PtdIns-4-phosphate (Rameh et al., 1997a; Rameh et al.,
1997b; Zhang et al., 1997). Class III PI3K uses Ptdlns as substrate. The term D-3
phosphoinositides is used for the lipid products produced by PI3-K (Rameh et al.,
1997a; Rameh et al., 1997b; Zhang et al., 1997). D-3 inositides work as secondary
signaling molecules whose functions include the recruitment o f cytoplasmic proteins
to the cell membrane and the alteration o f the activity o f the cytoplasmic proteins
(Fruman et al., 1998; Vanhaesebroeck eta l., 1997a).
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Figure 3.

The Structure o f Phosphatidylinositol.
Hydroxyl group on the third position o f the head group is subject to
phosphorylation by P13-Kinase. Phosphate joins the head group with fatty
acid tail.

22

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

The

activation

of

growth

receptors

is

known

to

activate

the

phosphatidylinositol 3-kinase (PI3-K) pathway. The current model for the PDGFpR
mediated activation o f the class IA PI3-K pathway is that the phosphorylated tyrosine
740 and 751 directly or indirectly associates with the SH2 domains o f the regulatory
protein p85 (Escobedo et al., 1991a; Fantl et al., 1992; Kashishian et al., 1992;
Kazlauskas et al., 1992). This association triggers the dissociation o f pi 10 catalytic
subunit allowing p i

10

to migrate to the plasma membrane to contribute in the

production o f D-3 phosphoinocitides (Fruman et al., 1998; Vanhaesebroeck et al.,
1997a).

In addition to the growth factor receptor mediated induction o f PI3-K

activity, several secondary signaling molecules are know to stimulate PI3-K pathway.
Activated G proteins are known to activate class I PI3K pathways (RodriguezViciana et al., 1994). Among the G proteins, the small G protein Ras is known to
directly associate with p i 10 catalytic subunit o f class IA and class Ib PI3-Ks (Fruman
et al., 1998; Vanhaesebroeck et al., 1997a). In addition, the Py subunits o f G proteins
have been shown to activate class Ib PI3K (L. Stephens et al., 1994; Stoyanov et al.,
1995; X. Tang & Downes, 1997).
Among the three classes o f PI3-K, Class I PI3-K is the best characterized.
The functional class I PI3-K exists as a heterodimer that consists o f a pi 10 catalytic
subunit and a regulatory subunit. Furthermore, the class I PI3-K is subdivided into
classes IA and Ib based on the type o f regulatory subunit that is present (Songyang et
al., 1993). The mammalian class IA PI3-K is composed o f one p i 10 catalytic subunit
a , p, and

8

that associates with a regulatory subunit that contains two src-homology
23
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2

(SH2) domains in the carboxy (C) terminus (Domin & Waterfield, 1997). Several
reports indicate that the

8

isoform is abundant in leukocytes (Domin & Waterfield,

1997; Vanhaesebroeck et al., 1997b), therefore the 5 isoform is presumably absent in
the cells o f astrocyte origin and fibroblasts. There are three genes that are known to
encode five different regulatory subunit o f class IA PI3-K (Domin & Waterfield,
1997). Five isoforms of the regulatory subunit are derived from three genes and they
are named as p85a, p85p, p55a, p55y, and p50a depend on the size o f the regulatory
protein (Vanhaesebroeck et al., 1997a). Among the isoforms, p 8 5 a contains not only
two SH2 domains but also a N-terminus src-homology 3 (SH3) domain, two proline
rich regions, and a RhoGAP homology domain. The p55a and p 5 0 a isoforms lack
the N-terminal SH3 domain, one proline rich domain, and a RhoGAP homology
domain (Vanhaesebroeck et al., 1997a).

A domain located between the two SH2

domains is inter SH2 domain, that participates in binding o f the p i 10 catalytic subunit
o f class IA PI3K (Vanhaesebroeck et al., 1997a). All catalytic subunits o f class IA
pi 10 include a domain for Ras binding, a phospahtidyl inocitol kinase (PIK) domain,
a catalytic domain and a domain for binding to regulatory adapter proteins (Domin &
Waterfield, 1997). The PIK domain is unique to the kinases that belong to the PI3-K
family and it is thought to be involved in substrate presentation (Domin & Waterfield,
1997).

The regulatory protein o f class IA PI3K is known to increase lipid kinase

activity by a few fold upon activation and contributes for the recruitment o f lipid
kinase to the proximity o f the cell membrane (Backer et al., 1992; Carpenter et al.,
1993).
24
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The class Ib PI3K includes the catalytic subunit p i 10 y and a regulatory
subunit o f lOlkDa that lacks any homology to the regulatory subunit with SH2
domains (L. R. Stephens et al., 1997). It has been reported that the small G protein
Ras regulates class Ib PI3-K (Rubio et al., 1997).
The role o f PI3K is to increase the cellular concentration o f PtdIns-3,4-P 2 and
PtdIns-3 ,4 , 5 -P 3 , which are scarce in the normal cells that are rich in PtdIns-4-P,
Ptdins-4 ,5 -P 2, and PtdIns-3-P (L. R. Stephens et al., 1991; Toker et al., 1995). The
activation o f the PI3-K. pathway, causes an increase in PtdIns-3,4-P 2 and PtdIns-3,4,5P3 concentration in the cell, where they work as secondary messengers (L. R.
Stephens et al., 1991; Toker et al., 1995). Targets o f PtdIns-3,4-P 2 and PtdIns-3,4,5P 3 include proteins that contain pleckstrin-homology (PH) domains (Lemmon et al.,

1996; Rameh et al., 1997a; Touhara et al., 1994), SH2 domains (Bae et al., 1998;
Rameh et al., 1995), protein kinase C (PKC) (Newton, 1997), clathrin adaptor
proteins (Rapoport et al., 1997), and actin regulatory proteins (Hartwig et al., 1996;
Sohn et al., 1995; Yu et al., 1992).
Among the downstream effectors o f PI3-K signaling, the Akt kinase has been
extensively studied due to its roles in activating molecules essential for cell survival
(Burgering & Coffer, 1995; Franke et al., 1995).

The AJct kinase contains a PH

domain that is required to receive the PI3-K signaling (Franke et al., 1995; Klippel et
al., 1996). The full activation o f Alct kinase seems to require not only the binding o f
D-3 inocitides to the PH domain, but also the phosphorylation o f threonine 308 and
serine 473 by phosphoinositide-dependent kinase -1 (PDK-1) (Alessi et al., 1996).
25
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PtdIns-3,4-P 2 and PtdIns-3 ,4 ,5 -P 3 have been shown to potentiate the ability o f PDK.-1
to phosphorylate the Akt kinase (Alessi et al., 1997; Stokoe et al., 1997).

The

activated Akt kinase has been shown to activate Bad responsible for the inhibition o f
apoptosis (S. R. Datta et al., 1997; del Peso et al., 1997), Dck a and P responsible for
phosphorylating IicBa to activate NF-kB (Factor et al., 2001; Madrid et al., 2000;
Ozes et al., 1999; Romashkova & Makarov, 1999), glycogen synthase 3 a /p (GSK3
a /p ) to inhibit gluconeogenesis (Lochhead et al., 2001; Pap & Cooper, 1998),
mammalian target of rapamycin (mTOR) to initiate DNA and protein sysnthesis
(Peyrollier et al., 2000; Somwar et al., 1998), and Forkhead Drosophila homolog 1
rhabdomyosarcoma (FKHR) to initiate transcription o f genes required for the
inhibition o f apoptosis (Brunet et al., 1999; Shin et al., 2001; E. D. Tang et al., 1999;
Uddin et al., 2000) (Figure 4). PDGF B chain stimulation o f swiss NIH3T3 cells has
been shown to cause Akt activation and subsequent NF-icB activation through IkkIicBa activation (Romashkova & Makarov, 1999).
Among the four p i 10 iso forms, the a and P isoforms have been welldescribed in these literature and the two isoforms are known to be most catalytically
active among the isoforms. Growing evidence suggests that p i 10a and p i 10P have
different roles in the cells, which is supported by the finding that p i

10a

knockout is

lethal despite the fact that pi 10p is expressed (Bi et al., 1999). An mRNA sequence
comparison between human phasphatidylinocitoI-3-kinase alpha subunit (PIK3CA, gi
20535400) and human phasphatidylinocitol-3-kinase beta subunit (PIK3CA, gi
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5453893) with BLAST search shows very low homology, p lio p but not p i 10a
synergistically associates with Gpysubunit for activation (Kurosu et al., 1997). p i 10a
seems to be involved in cell growth as overexpressing p i 10a in 3T3-L1 adipocytes
increases mitogenesis (Frevert & Kahn, 1997).

In addition, suppressing p i 10a

results in the decrease in growth factor mediated mitogenesis in several cell types
(Roche et al., 1998; Siddhanta et al., 1998; Vanhaesebroeck et al., 1999). PDGF
mediated mitogenesis does not seem to require p i 10P (Roche et al., 1998).
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Figure 4.

PI3-K Pathway is a Downstream Pathway o f Growth Factor Receptors.
In a case o f PDGFp receptor, phosphorylation o f tyrosines 740 and 751
activates the PI3-K pathway. Downstream effectors includes kinases
(gray) and transcription factors (dark gray), which leads to cell growth and
survival.
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PDGF-Induced Gene Expression

In order to determine the PDGF p receptor activated signaling pathways and
the transcriptional induction o f immediate early genes (IEGs), Fambrough et al. have
used gene expression array to find

66

IEGs induced by PDGF p receptor signaling in

mouse fibroblast NIH3T3 cells (Fambrough et al., 1999). The F5Y mutant PDGF
P receptors lacking tyrosine residues known to be used for binding and activation o f
the PLCy, PI3K, SHP2, and RasGAP pathways still managed to induce 64 o f these
IEGs (Fambrough et al., 1999). Elimination o f the Grb2-binding site further reduced
induction o f IEGs. When a mutant PDGF P receptor whose RasGAP-binding site was
added back induced genes that were normally induced by interferons (Fambrough et
al., 1999).

Among the IEGs, many transcription factors were induced within 20

minutes to 2 hour post-stimulation o f the receptors. Among the transcription factors,
c-jun, JunB, and c-fos gene expressions was induced within 20 minutes post
stimulation and NF-kB related gene expression was upregulated within 2 hours post
stimulation (Fambrough et al., 1999). This finding, together with the fact that NF-kB
activity is high in several different types o f tumor cells that overexpress PDGF B
chain including glioblastoma (Bhat-Nakshatri et al., 2002; Murphy et al., 2001; Sliva
et al., 2002), suggests that NF-kB may play essential roles in PDGF B chain and
PDGFPR mediated transformation

29

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Transcription Factor NF- kB

N F- kB belongs to the NF-KB/Rel family o f transcription factors that includes

p50 (N F kB I), p65 (RelA),

p 52(NF k B2),

c-Rel, and RelB. The NF-kB/Rel family o f

protein share approximately a 300 amino acid N-terminal Rel homology domain
(RHD) that contains DNA binding and dimerization domains and the nuclear
translocation signals (NLS) (Verma et al., 1995). N F- kB binds to the kB motif o f a
target gene promoter region to initiate transcription o f the gene. The consensus kB
m otif has been elucidated as GGGRNNYYC (R = purines, Y = pyrimidines, and N =
any nucleotide) (Baeuerle, 1991) and the kB m otif exists in the regulatory part o f
genes responsible for immune responses, regulatory functions o f NF- kB, growth
control, cell metabolism and cell adhesion (Verma et al., 1995). Binding o f N F- kB
binding sequence is also dependent on sequences surrounding the binding site.
Most members o f the NF-KB/Rel family can form homo- or hetero- dimers
except RelB that only forms heterodimers with either p50 or p52 (Verma et al.,
1995). Although the p65-p50 heterodimeric complex o f the NF-kB molecule is the
most abundant in nuclei, existence o f homodimer p50-p50 or p65-p65 has been
reported (Baeuerle, 1991). p50-p50 or p52-p52 homodimers can translocate into the
nucleus due to the presence o f a nuclear translocation signal on p50 and p52
molecules (Baeuerle, 1991) and can bind to the 5’ GGG o f NF-kB binding motif
(Urban & Baeuerle, 1990), but the homodimers are unable to initiate transcription due
to a lack o f transcriptional activation (trans-activation) domain (Verma et al., 1995).
30
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Several reports indicate that p50 and p52 subunits associate with nuclear IicB Bcl-3 to
enhance transcription initiation in several cell types (Bundy & McKeithan, 1997;
Cogswell et al., 2000; Dechend et al., 1999; Heissmeyer et al., 1999). c-Rel and p65
contain both RHD and transcription activation domains and the homodimeric forms
of these proteins are capable o f binding to

kB

motif o f target genes and initiating

transcription o f the target genes.
As shown in Figure 5, a current model suggests that inactive N F - k B exists in
the cytoplasm primarily as a heterotrimer o f the proteins p50, p65 and Ik B gc. This
complex remains in the cytoplasm due to the masking o f the nuclear localization
signal sequence o f the p50/p65 dimer by the IkB family o f proteins that are rich in
ankyrin repeats (Ganchi et al., 1992). Upon an appropriate stimulus, hcBa becomes
phosphorylated at serine 32 and 36 by one o f several different kinases including IkB
kinase P (IKK-p), causing its ubiquitination and eventual degradation by the 26S
proteosome (Verma et al., 1995). When IkB dissociates from the p50/p65 complex,
the active p50/p65 dimer translocates to the nucleus, binds to its target sequences, and
regulates transcription (described in Figure 5) (reviewed in (Finco & Baldwin, 1995;
Rice & Ernst, 1993)).
IKK-P seems to be a key regulator o f NF-kB as acetylsalicylic acid (ASA) has
been shown to inhibit cell growth by inhibiting IKK-P which results in the decrease in
activation o f NF-kB (Yin et al., 1998) (Figure

6

).

Epidemiological studies have

indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) such as ASA can
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decrease mortality 40%-50% in individuals with colorectal cancers (Smalley &
DuBois, 1997) and reduce colon cancer cell growth (Tsujii et al., 1998). ASA have
several known functions within cells. Both can irreversibly acetylate both isoforms
o f prostaglandin synthase (PGHS) (Bhattacharyya et al., 1995; Mancini et al., 1997;
Roth et al., 1983) causing a reduction in the synthesis o f prostaglandins (Castano et
al., 1997; Shier & Durkin, 1982).
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Figure 5.

A Current Model o f the p50-p65 NF-icB Regulation.
Upstream signals from growth receptors initiate the dissociation o f
Ikky from an Ikka and Ikkp complex. Dcka and Ikkp phosphorylate serine
42 on a regulatory protein ItcBa. hcB athen releases the p65-p50
heterodimer o f NF-tcB. Active NF-kB translocates into the nucleus and
initiates transcription.
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Figure 6 . Inhibition o f the NF-icB Activity by Aspirin.
Aspirin is known to inhibit an upstream kinase, Ikkp, responsible for
phosphorylating the IicBa regulatory protein causing it to release the p65p50 heterodimer.
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Nuclear Factor -tcB (N F-kB) is a transcription factor that regulates the
expression o f a variety o f cellular genes (Perkins et al., 1992) and is involved in focus
formation by the Ha-ras and the a b l oncogene. It is also activated in breast tumors,
glioblastomas, and non-Hodgkins lymphomas (T. S. Finco et al., 1997; Murphy et al.,
2001). It has recently been reported that NF-kB can stimulate the expression o f the
Cyclin D l gene and that this is a central feature of movement from G I into S phase
(Guttridge et al., 1999; Hinz et al., 1999). Several reports have indicated that NF-kB
can be activated by PDGF (Olashaw et al., 1992; Romashkova & Makarov, 1999).
Although NF-kB plays a central role in transformation induced by Ha-ras and Bcr-abl
(T. Finco et al., 1997; Reuther et al., 1998), nothing is known concerning its role in
transformation by PDGF.

Post-transcriptional gene silencing (PTGS)

Post-transcriptional

gene

silencing

(PTGS)

is also

referred

as “co-

suppression” in plants, “RNA interference” in Drosophila and C. elegans, and
“quelling” in fungi. The finding o f the RNA interference phenomenon stems from a
rather interesting accident (Gura, 2000). Researchers were trying to overexpress a
gene coding for an enzyme responsible for the pigmentation o f the petunias in an
attempt to produce purple petunias. Strangely, the overexpression resulted in the
production o f petunias with virgin white or variegated flowers (Gura, 2000).
Interestingly enough, some o f the phenotype could not be passed down to the
generations suggesting the phenomenon pertained to RNA modification (Gura, 2000).
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RNA interference has been observed in plants, C. elegans (Fire et al., 1998;
Grishok et al., 2000; S. Guo & Kemphues, 1995; Hunter, 2000; Kamath et al., 2001;
Sharp, 2001; Sharp & Zamore, 2000; Tabara et al., 1998; Timmons et al., 2001;
Timmons & Fire, 1998), Drosophila (Dzitoyeva et al., 2001; Kennerdell & Carthew,
1998, 2000; Schmid et al., 2002; Worby et al., 2001), fungi, and recently in
mammalian cells.

It has been reported that transfecting long dsRNA activates the

protein kinase PKR, which phosphorylates and inhibits the translation initiation factor
eLF2a (Manche et al., 1992). The inhibition o f eLF2a resulted in the suppression o f
translation (Manche et al., 1992).

In addition, the transfection o f long dsRNA

induced the expression o f RNAse L, which is known to cause non-specific
degradation o f RNA in the cells (Minks et al., 1979).
It is known that dsRNAs less than 30 nucleotides in length do not induce the
PKR kinase pathway. As 21- to 22- nucleotide long siRNAs can induce RNA
interference in Drosophila embryo lysates (Elbashir et al., 2001b), introduction o f
siRNAs to mammalian cells was performed to see if it could induce gene-specific
silencing (Elbashir et al., 2001a).

siRNAs transiently transfected to mammalian

cultured cells resulted in up to 90% reduction in target RNA and protein levels
(Caplen et al., 2001; Elbashir et al., 2001a; Holen et al., 2002).

In addition, the

experiments revealed that the most effective siRNAs are 21 nucleotide dsRNAs with
2 nucleotide 3' overhangs. It was discovered that siRNA activity is very sequence
specific such that single base pair mismatches between the siRNA and a target
mRNA significantly reduce silencing (Elbashir et al., 2001a; Elbashir et al., 2001c).
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It must be noted that not all siRNAs are always effective in silencing the homologous
target genes and the reason is unclear (Elbashir et al., 2001c; Holen et al., 2002).
The exact mechanisms o f PTGS are still not clearly understood, but models
describing the steps involved in PTGS are beginning to emerge.

The first step

appears to be the amplification o f the double-stranded RNA in the cell. Depending
on the cell type, the double-stranded RNA is digested into short stretches o f 21-25
nucleotides by the enzyme named DICER, which is a member o f the RNase III family
o f dsRNA specific ribonucleases that progressively cleaves dsRNA in an ATPdependent manner (Hutvagner & Zamore, 2002; Sharp, 2001).

It seems that

amplified and digested RNA is around 25 nucleotides in length in plants (Hamilton &
Baulcombe, 1999) and between 21 and 23 nucleotides long in Drosophila cells
(Zamore et al., 2000) due to further processing o f the dsRNA to yield 19-21 bp with
each with 2-nucleotide 3' overhangs (Bernstein et al., 2001; Zamore et al., 2000).
Those short dsRNAs are small interfering RNAs (siRNAs) or guide RNAs
(Hutvagner & Zamore, 2002; Sharp, 2001).

The siRNA duplexes binding to a

nuclease complex to form the RNA-induced silencing complex (RISC).

An ATP

dependent separation o f the siRNA duplex seems to be required for activation o f the
RISC, which targets and cleaves the homologous mRNA approximately

12

nucleotides from the 3' end o f the siRNA (Hammond et al., 2001; Hutvagner &
Zamore, 2002; Nykanen et al., 2001; Sharp, 2001). Although the exact mechanisms
o f cleavage have not been fully elucidated, it has been proposed that each RISC is
composed of a single siRNA and an RNase that seems to be distinct from Dicer
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(Hutvagner & Zamore, 2002).

In addition to the two steps described above, an

amplification step by RNA-dependent RNA polymerase (Gura, 2000) has also been
observed in some cells.

U87-MG and U118-MG Cell

U87-MG and U118-MG glioblastoma (astrocytoma) cells were used to study
the role o f PI3-K. pathway in the PDGF mediated tumorigenecity. There are at least
three major advantages o f using U87-MG to study the roles o f PI3-K. First, the cell
has been shown to endogenously express PDGF-B chain and the cell growth is
dependent on PDGF expression and its autocrine loop (Chin et al., 1997; Kilic et al.,
2000; Pollack et al., 1990; Schilling et al., 1998). Consequently, it provides an ideal
model to study the relationship between PDGF mediated activation o f PI3-K and NFtcB activity without the exogenous addition o f PDGF-B chain.
observation can be made in a real tumor cell line.

In addition, the

Second, the cell does not

endogenously express PTEN (phosphatase and tensin homologue deleted on
chromosome 10), which is capable o f dephosphorylating phosphatidylinositol 3,4,5triphosphate (Laemmli, 1970), the product o f PI3-K (Downes et al., 2001; D. M. Li &
Sun, 1998; J. Li et al., 1997). Therefore, the PI3-K activity can be monitored without
inhibition by PTEN. The third advantage o f using U87-MG cell is that our laboratory
has shown that U87-MG exhibit constitutively high NF-kB activity (M urphy et al.,
2001 ).
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MATERIALS AND METHODS

Cell Lines

NIH3T3 fibroblast cells and U87-MG cells were obtained from the American
Type Culture Collection.

NIH3T3 cells were maintained in Dulbecco’s Modified

Eagle Medium (DM EM ; Life Technologies, Carlsbad CA) supplemented with 10%
calf serum (CS) and antibiotics (penicillin 100 U/ml and streptomycin lOOpg/ml)
unless otherwise noted.

U87-MG cells were maintained in Minimal Essential

Medium (MEM; Life Technologies, Carlsbad CA) supplemented with 10% fetal
bovine serum (FBS) and antibiotics (penicillin 100 U/ml and streptomycin lOOpg/ml)
unless otherwise

noted.

Lipofections

were

performed using

Lipofectamine,

Lipofectamine Plus (L ife Technologies, Carlsbad CA), GenePorter (Gene Therapy
Systems, San Diego CA), or Fugene

6

(Roche, Indianapolis, IN) according to

manufacturer’s specifications.

A ratio o f 2 pg o f DNA per 10 pi o f lipofection

reagent or 2 pg per 6 pi (Fugene

6

only) was used throughout these experiments.

Morphological transformation and transformation inhibition assays were
performed as follows. NIH3T3 cells alone or clones o f NIH3T3 cells that had been
transfected with the PDGF- B chain expressing plasmid and selected for their
expression o f the PDGF-B chain protein by Western blotting were seeded on 12 well
plates at lxlO 4 cells/well or 4 x l0 4 cells per 60mm dish. When inhibitors were used,
they were added in fresh medium immediately after the medium with the DNA was
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removed from the cells. Cells were grown in DMEM supplemented with 10% CS
and antibiotics until they were at least 90% confluent. The medium was then changed
to DMEM supplemented with 2% CS and antibiotics (with o r without inhibitors), and
cells were fed every 2-3 days for a period o f 10 days. Cells were fixed in either 100%
methanol or

100%

ethanol before staining with 1 % crystal violet.

To determine the effects o f IicB67CJ, a dominant negative mutant o f IicBa,
and p65AC, a dominant negative mutant o f p65, on PDGF-B chain transformation,
plasmids expressing these genes were transfected into NIH3T3 cells expressing the
PDGF-B chain.

Briefly, N1H3T3 cells were seeded on

8

well plates (4xl0 4

cells/well), and cells were co-transfected with the indicated amounts o f the different
plasmids as described above.

Cells were then grown, fed, and stained as described

above.
For Western blotting, NIH3T3 cells and U87-MG were seeded on 60mm
dishes (6 x l0 4 cells/dish). The NIH3T3 cells were co-transfected with plasmids that
expressed PDGF-B chain and p65, p65AC, or ItcB67CJ. U87-MG cells were
transfected with small interference RNA (siRNA) and reporter vector as indicated in
sections below.

Inhibitors and Chemicals

Concentrations o f inhibitors and chemicals were chosen based on previous
work by others (Conte et al., 1997; Goppelt-Struebe et al., 1996; Kopp & Ghosh,
1994; Tsujii et al., 1998).

NS398 (Calbiochem, San Diego, CA) was dissolved in
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100%

DMSO.

Prostaglandin

Ei (PGEi;

Biomol,

Plymouth

Meeting,

PA),

indomethacin, acetylsalicylic acid (ASA; Sigma, St. Louis, MS), and salicylic acid
(SA; Sigma, St. Louis, MS) were dissolved in 100% ethanol.

When aspirin was

dissolved in cell culture medium, the pH o f the medium was adjusted to 7.4.

Antibodies

Several antibodies were used throughout this study.

Anti NF-tcB p65 CT

rabbit polyclonal antibody (Upstate, Lake Plasid, NY) at 2p.g/ml for western blot and
5pg for electromobility shift assay (EMSA), anti NF- kJB p50 rabbit polyclonal
antibody (Upstate, Lake Plasid, NY) at 5|ig for EMSA, anti IicBa rabbit polyclonal
antibody (Upstate, Lake Plasid, NY) at 0.5pg/ml for western blot, anti p i 10a mouse
monoclonal antibody (Santa Cruz, Santa Cruz, CA) at 1:125 for western blot, anti
pllO P mouse monoclonal antibody (Santa Cruz, Santa Cruz, CA) at 1:125 for
western blot, anti PDGFP receptor rabbit polyclonal antibody (Upstate, Lake Plasid,
NY) at 2(ig/ml for western blot, anti IicBa rabbit polyclonal antibody (Upstate, Lake
Plasid, NY) at 2pg/ml for western blot and at 5pg/ml for immunoprecipitation, anti
pi 10a rabbit polyclonal antibody (Upstate, Lake Plasid, NY) at 4(ig/ml for
immunoprecipitation, and anti pllOP rabbit polyclonal antibody (Upstate, Lake
Plasid, NY) at 5(ig/ml for immunoprecipitation.
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Plasmid Constructs

A fragment o f the cDNA o f the PDGF-B chain that contained the complete
coding region was obtained by digestion o f the plasmid pSM-1 (Ratner et al., 1985)
with BamHI and then cloned into pCDNA3.I(-) (Invitrogen, Carlsbad, CA) digested
with the same restriction endonucleases. The pNF-tcBLuc reporter vector with four
tandem

repeats

o f the

invariant

chain

li, NF-kB

consensus

binding site

(GGGAATTCC) fused to a TATA-like promoter region from the Herpes simplex
virus thymidine kinase gene was obtained (BD Clontech, Palo Alto, CA). A clone
that lacked the four tandem repeats o f the NF-kB consensus binding site was created
by digestion o f the original plasmid with Kpnl and Bglll, followed by treatment with
E.coli DNA polymerase I and ligation.

The wild type N F-kB p65 gene and a

dominant negative mutant o f p65, p65AC, were the kind gifts o f Drs. Alain Israel and
Nancy Rice (Kieran et al., 1990; Rice & Ernst, 1993).

The pRcCMV vector

containing the IkBgc mutant, pMEIkB67CJ, expressed an hcba protein that can not be
phosphorylated and therefore forms highly stable complexes with the p50/p65
heterodimers (Whiteside et al., 1995). The p65AC gene encodes a p65 subunit that is
able to dimerize with the p50 subunit o f NF-kB but is unable to stimulate
transcription due to the lack o f c-terminal activation domain (Grimm & Baeuerle,
1994). RVY and RVY-E5, which can express the bovine papilloma virus E5 gene,
were the kind gifts o f Dr. Daniel DiMaio (Riese & DiMaio, 1995).
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NF-kB Reporter Assays

NIH3T3 Cells and Luciferase Reporter Assay

NIH3T3 cells were seeded on

8

well plates (6 x l0 4 cells/well). Sixteen to 24

hours after seeding, cells were co-transfected with the indicated amount o f the
reporter plasmid with the NF-kB binding sequences (NF+) or the plasmid that lacked
the NF-kB binding sequences (NF-) and other plasmids as the indicated ratios as
described above. Four hours post-transfection, DMEM supplemented with 10% CS
and antibiotics was added to the cells, and the cells were incubated for an additional
16-24 hours. Medium was then replaced with fresh DMEM supplemented with 10%
CS and antibiotics and incubated another 24 hours, after which the medium was
replaced with DMEM supplemented with I % CS. At 72 hours post-transfection, cells
that had been transfected with the growth factor expressing constructs were harvested.
Cells were harvested by washing 2-3 times in phosphate buffered saline (PBS,
137 mM NaCl, 2.7 mM KC1, 4.3 mM Na 2 H P O W H 2 0 , 1.4 mM KH 2 P 0 4, pH 7.4) and
lysed in luciferase assay cell culture lysis buffer (Promega, Madison, WI). Lysates
were centrifuged at 10,000 X g for 20 seconds and the pellets were discarded. The
lysates were assayed immediately or frozen at -8 0 C until use. Protein concentrations
were determined using the BCA assay (Pierce, Rockford, IL) with bovine serum
albumin (Sigma, St. Louis, MO) as a standard. Equal amounts o f protein were used
for luciferase assays with the Luciferase assay system (Promega, Madison, WI) or
LucLite

(Packard

Bioscience,

Boston,

MA)

according

to

manufacturers’
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recommendations.

Assays were performed at least three times, and results were

statistically analyzed using analysis o f variance (ANOVA) and the Student-NewmanKeuls (SNK) tests.

NIH3T3 Cells and Secreted Alkaline Phosphatase Assay

When reporter vectors with secreted alkaline phosphatase were used, NIH3T3
cells were seeded on 24 well plates (2xl0 4 cells/well) and allowed to grow in DMEM
supplemented with 10% CS until 70 % confluent. Cells were transfected with I fig o f
the pNF-»cBSEAP or pTAL, a negative control plasmid that lacks a NF-kB binding
sequence, and pMEhcB67CJ as indicated.

The amount o f plasmid used for

transfections was equalized between treatments by addition o f the appropriate amount
o f pRcCMV.

Four hours post-transfection, DMEM supplemented with 10% CS and

antibiotics was added to the cells, and the cells were incubated for an additional 24
hours.

Medium was then replaced with fresh DMEM supplemented with 10% CS

and antibiotics and incubated another 24 hours, after which the medium was replaced
with equal amounts o f serum free DMEM.

At 72 hours post-transfection,

supernatants from cells were harvested. The supernatants were centrifuged at 10,000
X g for 20 seconds and the pellets were discarded. The supernatants were assayed
immediately or frozen at -8 0 C until use. To measure the activity o f the secreted
alkaline phosphatase (SEAP), equal amounts o f supernatants were used for SEAP
assays with the Great EscAPe SEAP assay system (BD Clontech, Palo Alto, CA)
according to the manufacturer’s recommendations. Assay results were normalized
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for both protein and Pgal to take difference in cell density and transfection efficiency
into account. Assays were performed multiple times, and results were statistically
analyzed using analysis o f variance (ANOVA) and the Student-Newman-Keuls
(SNK) tests.

U87-MG Cells and Secreted Alkaline Phosphatase Assay

When reporter vectors with secreted alkaline phosphatase were used for
measuring NF-kB activity in U87-MG cells, U87-MG cells were seeded on

8

well

plates (6 x l0 4 cells/well) and allowed to grow in MEM supplemented with 10% FBS
until 80 % confluent. Sixteen to 24 hours after seeding, cells were triple-transfected
with the indicated amount o f the reporter plasmid with the NF-kB binding sequences
(NF) or the plasmid that lacked the NF-kB binding sequences (pTAL), plasmid
coding for P- galactosidase and other plasmids or short interfering RNA (siRNA) as
the indicated ratios as described.

When U87-MG cells stably transfected with

PDGFPR were used, cells were seeded on

8

well plates (8 x l0 4 cells/well) and

allowed to grow in MEM supplemented with 10% FBS for 24 hours. The cells were
co-transfected with the indicated amount o f the reporter plasmid with the NF-kB
binding sequences (NF) or the plasmid that lacked the NF-kB binding sequences
(pTAL) and plasmid coding for P- galactosidase. Four hours post-transfection, MEM
supplemented with 10% FBS and antibiotics was added to the cells, and the cells
were incubated for an additional 24 hours. Medium was then replaced with fresh
MEM supplemented with 10% FBS and antibiotics and incubated another 24 hours.
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At 48 hours post-transfection, supernatants from cells were harvested.

The

supernatants were centrifuged at 10,000 X g for 20 seconds and the pellets were
discarded. The supernatants were assayed immediately or frozen at -80°C until use.
To measure the activity o f the secreted alkaline phosphatase (SEAP), equal amounts
o f supernatants were used for SEAP assays with the Great EscAPe SEAP assay
system

(BD

Clontech,

Palo

Alto,

CA)

according

to

the

manufacturer’s

recommendations. Assay results were normalized for both protein and Pgal to take
difference in cell density and transfection efficiency into account.

Assays were

performed multiple times, and results were statistically analyzed using analysis o f
variance (ANOVA) and the Student-Newman-Keuls (SNK) tests.

Western Blotting

Western blots were performed as described below. Briefly, 80% confluent
monolayers o f cells were rinsed 2 times with IX PBS and then lysed in lysis buffer
(20 mM Tris HC1 pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X100, 2.5 mM sodium pyrophosphate, 1 mM P-glycerophosphate, 1 mM sodium
vanadate, 1 mM PMSF, 1 pg/ml leupeptin). Lysates were recovered and centrifuged
at 12,000 X g for 10 minutes and the pellets discarded. The protein concentrations in
the lysates were measured using the BCA assay (Pierce, Rockford, IL) and equal
amounts o f protein samples were resolved on a 10 % SDS-PAGE gel (Laemmli,
1970). After electrophoresis, the proteins were transferred to a PVDF membrane.
The membrane was blocked with blocking buffer, 0.25 % I-Block (Tropix, Bedford,
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MA) in Tris buffered saline with Tween 20 (TBS-T; 19.98mM Tris HC1 pH 7.6,
136.75mM NaCl, 0.01 % Tween 20).

After 2 hours at room temperature, the

membrane was incubated with an antibody directed against target protein in blocking
buffer. The membrane was washed twice for 5 minutes in TBS-T followed by a wash
for 10 minutes in TBS-T.

The membrane was then incubated with anti-rabbit

antibody conjugated to horseradish peroxidase (Amersham Biosciences, Piscataway,
NJ). The blot was then washed as described above before incubation with the ECL
reagent (Amersham Biosciences, Piscataway, NJ) and exposed to Kodak X-Omat film
(Eastman Kodak, Rochester, NY).

Preparation o f Nuclear Extract

Nuclear extracts were prepared as described previously (Murphy et al., 2001;
Paulose et al., 1998).

Cells were cultured in 150mm dishes with DMEM

supplemented with 10% calf serum and allowed to achieve approximately 80%
confluence. After washing cells with IX PBS (137 mM NaCl, 2.7 mM KC1, 4.3 mM
Na2HPO4*7H20, 1.4 mM KH 2 PO 4 , pH 7.4), cells were removed from the dishes by
trypsin and centrifuged at 2000xg for 5 minutes at 4°C.

The supernatant was

discarded, and the cell pellet was resuspended in I ml buffer A (lOmM HEPES,
pH7.9,

1.5mM

MgCl2,

lOmM

KC1,

0.1%

NP-40,

ImM

NaF,

ImM

phenylmethylsulfonylfluoride (PMSF, Sigma, St. Louis, MO) and 0.5mM DLDithiothreitol (DTT, Sigma, St. Louis, MO) and centrifuged again at 2,000xg for 5
minutes at 4°C. The supernatant was decanted and the cell pellet was completely
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resuspended in 80|il o f buffer A with 0.1% triton x-100 (Sigma, St. Louis, MO). The
suspension was then incubated on ice for 30 minutes and centrifuged at 2,000xg for 5
minutes at 4°C. The supernatant was discarded, and the resultant nuclear pellet was
resuspended in 60pl buffer C (20mM HEPES, pH7.9, 0.42M NaCl, 25% (v/v)
glycerol, l.5m M MgCL, ImM NaF, Im M PMSF, and 0.2mM EDTA).

The

suspension was incubated on ice for 30 minutes followed by centrifugation at
16,OOOxg for 20 minutes at 4°C. The resultant supernatant was the nuclear extract.
Total protein concentration o f the extract was measured immediately after preparation
by using the colorimetric bincinchoninic acid (BCA) assay (Pierce, Rockford, IL),
and the nuclear extract was stored at -80°C until use.

Electrophoretic Mobility Shift Assay

Electrophoretic Mobility Shift Assay (EMSA) was performed in 40pl
containing 40pg o f total nuclear protein with 1 pmol oligo containing a icB motif
(consensus NF-tcB binding sequence from mouse Ig k light chain; 5’-AGT TGA GGG
GAC TTT CCC AGG C-3’) and its complement (5’-G CCT GGG AAA GTC CCC
TCA ACT-3’) labeled with y-32P ATP in binding buffer (lOmM HEPES, 50mM KC1,
2.5mM dithiothreitol, 0.2mM EDTA, 0.05% nonidet-P40, and 10% glycerol, pH7.9).
Competition assays were performed by incubating lpm ol o f 32P labeled oligo
containing the tcB m otif together with 50 fold excess o f unlabeled oligonucleotide.
Samples were electrophoresed on a 7% native polyacrylamide gel in low ionic
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strength Tris-glycine buffer (50mM Tris, 380mM glycine, and 0.2mM EDTA,
pH8.5). Following electrophoresis, the gel was exposed to storage phoshor screen
(Eastman Kodak, Rochester, NY) for an hour, and the screen was analyzed with an
860 Storm™ Fluorlmager (AmerishamPharmacia Biotech, Piscataway, NJ).

Fluorescent Electrophoretic Mobility Shift Assay

Fluorescent electrophoretic mobility shift assays (FEMSA) were performed as
described (Murphy et al., 2001). Briefly, assays were performed in 40ul volumes
containing 20pg o f nuclear protein incubated with lpm ol o f the FAM (492nm
absorption and 515nm emission) labeled oligonucleotides (NF-icB, Research
Genetics, Carlsbad CA).

Oligonucleotides that contained the consensus binding

sequence for NF-kB binding were used (FAM-CATGAACCGGGAATTTCCAACA
TG-Dabcyl and its complement AATTGGAAATTCCCGGTTCC). Oligonucleotides
with the same sequence that were not labeled as well as oligonucleotides that
contained two point mutations that had previously been shown to abolish NF-icB
binding (CATGAACCCGCAATTCCAACATG and its complement AATTGGAAA
TTGCGGGTTCC ) were used as competitive and non-competitive inhibitors for
binding with the labeled oligonucleotides (Murphy et al., 2001).

Assays were

performed in total volume o f 40 pi with binding buffer (lOmM HEPES, 50mM KC1,
2.5mM DTT, 0.2mM, 0.05% NP-40, 10% glycerol, pH 7.9).

Competition

experiments were performed by adding the appropriate competitor oligonucleotides at
a 50 fold molar excess with the labeled oligonucleotides prior to the addition of the
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cell lysate. The supershift assays were performed by adding 0.5 pmol o f antibody to
the p65 subunit o f NF- kB (Upstate, Lake Placid, NY) to reactions that contained
labeled oligonucleotides without a competitor. Samples were electrophoresed on a
7% native polyacrylamide gel in low ionic strength Tris-glycine buffer (50mM Tris,
380mM glycine, and 0.2mM EDTA, pH8.5).

After electrophoresis the gel was

analyzed by blue-excitation fluorescence scanning with an 860 Storm™ Fluorlmager
(Amerisham Pharmacia Biotech, Piscataway, NJ).

Akt Kinase Asssay

To measure the activity o f PI3-K activity, 8X104 U87-MG cells were seeded
on 60 mm dishes and allowed to grow for at least 24 hours to achieve 80%
confluence. The cells were transfected with different amount o f siRNA (including
optimal amount determined from earlier experiment) and the cells were lysed with
lysis buffer (20m M Tris (pH7.5), l50mM NaCl, ImM EDTA, ImM EGTA, 1%
Triton X-100, 2.5mM sodium pyrophosphate, ImM P-Glycerophosphate, ImM
Sodium Orthovanadate, Ipg/m l Leupeptin) at 24 hours post transfection. Lysates
from the samples were collected and sonicated briefly while the samples were kept on
ice. Then the lysates were centrifuged at 14,000xg for 5 minutes at 4 °C. Then the
supamatents were collected. Total protein concentration o f the extract was measured
immediately after preparation by using the colorimetric bincinchoninic acid (BCA)
assay (Pierce, Rockford, IL), and the lysates were stored at -80°C until use. Lysates
were then subject to immunoprecipitation with immobilized active Akt antibody (Ser
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308 Thr 473) to capture active Akt in the lysates. The immunocomplex was washed
twice in the lysis buffer then two times in kinase assay buffer (25mM Tris (pH7.5),
5mM p-glycerophosphate, O.lmM sodium orthovanadate, 2mM DTT, lOmM MgCb).
After the wash, the collected active Akt was subject to a kinase assay by incubating
active Akt with substrate GSK-3a/p fusion proteins (lpg/sam ple) supplemented with
200pM ATP for 30 minutes at 30 °C. The kinase reaction was terminated by adding
3X sample preparation buffer (l87.5m M Tris-HCl (pH 6.8 at 25 °C), 6% w/v SDS,
30% glycerol,

150mM

DTT, 0.03%

w/v bromophenolblue) and vortexing.

Supernatant was then resolved on a 10% Tris-Glycine gel and Western blot was
performed. In principle, active Akt phosphorylates G SK -3a/p on serine 9 and 21 and
the phosphorylated serine residues can be determined by the incubation with antiphospho-GSK-3 ct/p serine 21/9 antibody on Western blot.

Immunoprecipitation

Immunoprecipitation o f pi 10a and pllO P was performed to determine the
expression o f these proteins under siRNA treatment. 150(j.g/200jj.l o f lysate was pre
cleared with 10pl o f protein A/G plus agarose (Santa Cruz, San Diego, CA) before
incubation with an anti p i 10 antibody (Upstate, Lake Placid, NY) at concentrations
described in antibody section o f Materials and Methods above. This mixture was
incubated for 2 hours at 4 °C. 50pl protein A/G plus agarose (50% v/v) was added to
the antibody and lysate mixture and the mixture was incubated for 1 hour at 4 °C on a
rocker table.

After the incubation, the agarose beads were collected by pulse
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centrifugation and washed three times with PBS supplemented with ImM NaF and
ImM PMSF. The collected beads-antibody-protein complex was mixed with 60|il o f
2X sample buffer, vortexed, and centrifuged.

The supernatant was collected and

boiled for 5 minutes before resolving on an SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) (Laemmli, 1970).

Design and Transfection o f siRNA

The siRNA was designed according to the published specifications available
by literatures (Elbashir et al., 2001a; Elbashir et al., 2001b; Elbashir et al., 2001c).
From the AUG start codon o f target mRNA, AA dinucleotide sequences were
searched. The 3' adjacent 19 nucleotides were considered as potential siRNA target
sites. The effective siRNA to suppress mRNA expression should be homologous to
the sequence within 75 bases from start codon o f the target mRNA sequence
(Elbashir et al., 2001a; Elbashir et al., 2001b; Elbashir et al., 2001c).
content o f the siRNA should be between 30 - 40%.

The GC

Once the 21 nucleotide siRNA

was designed, the sequence was compared against the appropriate genome database
(human, mouse, rat, etc.) such as Basic Local Alignment Search Tool for nucleotide
(BLASTn) from National Center for Biotechnology Information (NCB1) and some
siRNA were eliminated from consideration due to significant homology to other
coding sequences.
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This was particularly important as siRNA against p i 10a should silence the
expression o f p i 10a, but it should not inhibit the expression o f p i 10(3 or other
essential mRNAs in the cells. In addition, negative control should be prepared.
For the p i 10a, the Homo sapiens phosphoinositide-3-kinase alpha catalytic
subunit polypeptide PDC3CA mRNA (NM 006218) sequence from genebank was
used to design the siRNA.
siRNA against p i 10a was designed as follows.
Sense: AUG GAA UGA UAG UGA CUU U dTdT
Anti-sense: dTdT UAC CUU ACU AUC ACU GAA A
The Control siRNA against p i 10a was designed as follows.
Sense: UUU CAG UGA UAG UAA GGU AdTdT
Anti-sense: dTdT AAA GUC ACU AUC AUU CCA U
For the pllO p, Homo sapiens phosphoinositide-3-kinase alpha catalytic
subunit polypeptide PEK.3CB mRNA (NM_006219) sequence from genebank was
used to design the siRNA.
siRNA against pi 10P was designed as follows.
Sense: UUG CUU CCA UAA CAU CUG CdTdT
Anti-sense: dTdTA ACG AAG GUA UUG UAG ACG
Control siRNA against p i 10p was designed as follows.
Sense: GCA GAU GUU AUG GAA GCA AdTdT
Anti-sense: dTdTC GUC UAC AAU ACC UUC GUU
All siRNAs used in this study were obtained as 2 ’-ACE protected
(Dharmacon Research, Lafayette, CO) for stability. Equimolar concentration o f each
strand o f siRNA was suspended in 2 ’-deprotection buffer (lOOmM Acetic acid,
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adjusted to pH 3.8 with TEMED) and combined. The mixture was incubated at 60 °C
for 30 minutes followed by incubation at room temperature for 30 minutes. The
resultant double stranded RNA (siRNA) was ethanol precipitated and lyophilized.
The working siRNA solution was prepared in IX annealing buffer and optical density
at 260 and 280nm was measured to determine the concentration o f the sample. The
concentration of siRNA sample used in this study was consistently adjusted to
Ipg/pl.
In order to test the effect o f the siRNAs in the cells, 80% confluent U87-MG
cells were transfected with different concentrations o f siRNA against either p i 10a or
pi 10p. 0, 1, and 2 pg siRNA per 60mm were used initially as the concentrations had
been reported to be effective to suppress the expressions o f luciferase gene in insect
cells (Elbashir et al., 2001a; Elbashir et al., 2001b; Elbashir et al., 2001c). Control
siRNA that has same number o f nucleotides, but the sequence is random so that the
sequence is no longer homologus to the target mRNA. Lipofections were performed
using Fugene 6 (Roche, Indianapolis, IN) according to the manufacturer’s
specifications. A ratio o f 2 pg o f DNA per 6 pi (Fugene 6 only) was used throughout
these experiments.

Transfected cells were harvested at 24, 32, and 48 hrs post

transfection to find an optimal time point and lysate was collected. The effect o f
siRNA was tested by using Western blots to determine the expression level o f the
target protein.
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RESULTS

Activation o f NF-icB in PDGF-B Chain Transformed NIH3T3 Cells

ASA Inhibits PDGF B Chain Induced Focus Formation

As some colon tumors that are known to over-express PDGF-B chain (Hsu et
al., 1995) some colon cancer cells are sensitive to ASA (Rosenberg et al., 1998), we
hypothesized

that

ASA

might

potentially

inhibit

PDGF-B

chain

induced

transformation. NIH 3T3 cells were transfected with a plasmid that constitutively
expresses the PDGF B chain (Ratner et al., 1985), and a cell line that expressed the
PDGF-B chain homodimer was identified by Western blotting (data not shown).
Cells were subjected to treatment with DMEM supplemented with 2% calf serum
(CS) and ASA or SA in solvent (ethanol). The results (Figure 7A) demonstrated that
the addition o f either ASA or SA potently inhibited focus formation in these cells.
The solvent control did not affect normal cell growth and resulted in much higher cell
density than that of ASA or SA treated cells masking individual foci. Inhibition by
ASA and SA was not due to an altered pH o f the medium as the pH o f the medium
was re-established at 7.4 after ASA or SA addition. The concentration o f ASA and
SA used in this assay was not toxic to the cells as cells grew normally after removal
o f ASA and SA from the media (data not shown).
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To determine if the inhibition o f focus formation caused by ASA was due to
its inhibition o f prostaglandin synthesis, two inhibitors o f prostaglandin synthesis
were tested for their effects on focus formation. In contrast to the results obtained
with ASA and SA, treatment o f cells w ith NS398 which preferentially inhibits
prostaglandin H synthase (PGHS2; COX2) (Tsujii et al., 1998) did not result in a
decrease in focus formation even with the concentration known to completely inhibit
PGHS2 (10pM) (Attiga et al., 2000; Q. Guo et al., 1996) (Figure IB). In a same
manner, indomethacin, which inhibits both PGHSl and PGHS2 (Kopp & Ghosh,
1994) did not result in a decrease in focus formation even at concentrations well
above those known to inhibit PGHS activity (Figure 7B).
To further confirm that the inhibition o f focus formation by ASA was not due
to its inhibition o f prostaglandin synthesis, we performed focus formation assays in
the presence o f ASA and PGE 2 . PGEi is the major prostaglandin produced by PDGF
stimulation o f fibroblasts and PGEi addition to medium can restore PDGF stimulated
DNA synthesis that has been inhibited by ASA (Shier & Durkin, 1982). Addition o f
PGE 2 to PDGF-B chain transfected cells does not significantly affect focus formation
either in the presence or absence o f ASA (Figure 8).

NF-icB Activity in PDGF B Chain Overexpressing NIH3T3 Cells

Previous reports have indicated that ASA and SA but not other NSAIDS may
also inhibit the activity o f the transcription factor NF- kB (Kopp & Ghosh, 1994). We
were, therefore, interested in determining if NF-icB was significantly activated in
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PDGF-B chain transformed NIH3T3 cells and, if so, what effects ASA and SA had on
this activation. NIH3T3 cells were transiently co-transfected with the NF-icB reporter
vector containing 4 tandem repeats o f invariant chain li NF-icB binding sequence or
the reporter vector that completely lacked the NF-tcB binding sequences.

These

plasmids were co-transfected w ith an empty expression vector, a plasmid that
expressed the PDGF-B chain pSM -l (Ratner et al., 1985).
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Figure 7.

Number of Foci
Control

25+9

31+9

5pM

27+13

25.5±2.5

10pM

23+8

27+3

20pM

9±l

24+7

50pM

0

17

ASA Inhibits Focus Formation Caused by PDGF-B Chain Gene
Expression.
Clones o f NIH3T3 cells that constitutively express the PDGF-B chain
were seeded on 12 well plates and treated with different inhibitors in
DMEM supplemented with 2% CS and antibiotics. A) Cells treated with
ASA or SA. Note that absence o f ASA or SA (Control) promoted
excessive cell growth that masked foci. ASA was more effective than SA
at inhibiting PDGF-B chain induced focus formation. B) Cells treated with
PGHS2 inhibitors NS398 or indomethacin (IND). PGHS2 inhibitors were
not effective at inhibiting PDGF-B chain induced focus formation
compared to ASA. As complete inhibition o f PGHS2 by NS398 occurs at
concentrations below lOmM, the decreased focus formation in 20 and 50
mM NS398 was not due to the inhibition o f PGHS2 but probably due to
secondary effects. Control indicates cells treated with solvent alone
(either ethanol or dexamethasone). Cells were fixed in either methanol or
ethanol before being stained with 1% crystal violet. In the tables above,
numbers indicate number o f foci per well.
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PDGF-B chain

PDGF-B chain
+ASA
5±1

266.7+37.1

PDGF-B
chain+PGE2
206.7+35.3

PGE 2 Does Not Rescue Focus Formation Inhibited by ASA.
NIH3T3 cells were transfected with the plasmid that expresses the PDGFB chain gene (PDGF-B).
Cells were then treated with DMEM
supplemented with 2% CS alone or supplemented with 5mM ASA or both
ASA and 500 nM PGEt or 500 nM PGE2 alone. After 10 days, cells were
fixed with ethanol and stained with I % crystal violet. In the table above,
numbers o f foci per plate are shown.
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or a plasmid that expressed the E5 protein from Bovine Papilloma virus. The results
(Figure 9) demonstrated that both o f the plasmids that expressed genes that could
activate the PDGF receptors, pSM-1 and the E5 construct (Kilk et al., 1996; L. Petti
et al., 1991; Riese & DiMaio, 1995), were able to cause a significant and substantial
increase in NF-kB activity. The NF-kB activity was increased more than 2 (pSM-1)
and 3.8 (E5) fold as compared to the NF-kB activity in either cells transfected with
the reporter vectors lacking the NF-kB binding sequences or cells transfected with its
empty expression vectors. Similar results were obtained when NIH3T3 cells were
transfected with the NF-kB reporter vectors and the cells then stimulated with
exogenous PDGF-B chain homodimer 72 hours post transfection (data not shown).

ASA to Suppress NF-kB Activity in PDGF B Chain Overexpressing NIH3T3 Cells

This activation o f NF-kB in PDGF-B chain over-expressing cells was
significantly reduced upon treatment o f the transfected cells with ASA (Figure 10).
NTH3T3 cells that were transfected with pSM-1 and either a reporter vector with the
NF-kB binding sites or a reporter vector without the NF-kB binding sites before
treatment with ASA.

The results clearly show that, as before, pSM -l induced a

greater than 2 fold increase in NF- kB activity as compared to cells that were
transfected with the reporter vector lacking the NF-kB binding sequences and a
greater than 1.5 fold increase in NF- kB activity as compared to cells that had been
transfected with the vector control. When compared to cells that were treated with
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ASA, cells co-transfected with pSM-1 and the reporter plasmid that contained the
NF-tcB binding sites had a significantly higher level.
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Figure 9.

PDGF-B Chain Over-expression Promotes NF- kB Activity.
NIH3T3 cells were transfected with plasmids that express PDGF-B chain
gene (PDGF-B) or the bovine Papilloma virus E5 gene (E5) or empty
vector (RVY) and either the reporter plasmid that contains the NF- kB
binding sequences (NF+) or the reporter plasmid that lacks the NF- kB
binding sequences (NF-). Luciferase assays were performed three times,
and the results were averaged. Luminescence was expressed as fold
increase against control compared to the results from cells that were co
transfected with RVY and the reporter plasmid that contains the NF- kB
binding sequences (RVY & NF+). Activation o f NF- kB by PDGF-B (*)
or E5 (**) was significantly greater than others (p < 0.05, ANOVA and
SNK tests).
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Fold Increase in Luciferase Activity

2

Figure 10. ASA Decreases NF-k B Activity in PDGF-B Chain Expressing Cells.
NIH3T3 cells were transfected with either the plasmid that expresses the
PDGF B chain gene (PDGF-B) or the empty expression vector alone
(pCDV-1) in conjunction with the reporter plasmids that either contain
the N F - kB binding sequences (NF+) or lack the NF- kB binding
sequences (NF-). Luciferase activity was expressed as fold increase over
the control (pCDV-l & NF+). Activation o f NF- kB by PDGF-B (PDGFB & NF+) was significantly greater than the control (pCDV-1 & NF+)
and was reduced by ASA treatment to background levels (p < 0.05,
ANOVA and SNK tests).
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o f activity than those cells that had received ASA treatment. In fact, the levels o f
luciferase under these conditions had been reduced to background (compare pCDV1&NF+ and pSM -l& N F+ ASA treated.).
Electrophoretic mobility shift assays (EMSA) were performed to confirm the
presence o f NF-kB in the nucleus. As shown in Figure 11, it was clear that NF-kB
DNA binding activity was greatly increased in PDGF-B chain over-expressing cells
(PDGF-B chain-ASA), and the increase was approximately 2 fold more than the NFkB

DNA binding activity observed in control cells.

When PDGF-B chain over

expressing cells were treated with ASA (PDGF-B Chain+ASA), DNA binding
activity was decreased approximately 50% compared to DNA binding activity
observed in control cells (vector control).

Suppression o f N F- kB Activity to Inhibit PDGF B Chain Transformation

As ASA appeared to be controlling focus formation and inhibiting N F- kB
promoter and DNA binding activities in PDGF-B chain expressing NIH3T3 cells, we
were interested in a more direct test of the effect o f N F - k B on focus formation. Two
dominant negative mutants were used in transfection assays. One was a mutant o f
IkB oc, IkB 67C J, that can not be phosphorylated and therefore, forces the retention o f
N F- kB/I kB complexes in the cytoplasm. The second was a dominant negative

mutant o f p65, p65AC, that lacked the transactivation domain o f p65 and, therefore,
could form heterodimers that were translocated to the nucleus but can not activate
transcription (Grimm & Baeuerle, 1994).
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Figure 11. PDGF-B Chain Over-expression Increases NF-teB Binding Activity
Which is Inhibited by Treatment With ASA.
Stable NIH3T3 cell lines that were transfected with either the plasmid
that expresses the PDGF-B chain gene (PDGF-B) or the empty
expression vector (Vector Control) were established. The PDGF-B chain
gene transfected cells were grown in DMEM supplemented with 10%
calf serum in the presence o f 500 pM ASA (+ASA) or the absence o f
ASA (-ASA). All lanes contained lpmol o f 32P labeled oligonucleotides
that contained the tcB motif. The competition lane included nuclear
extract from PDGF-B chain expressing cells, labeled oligonucleotides
and a 50 fold excess o f unlabeled oligonucleotides.
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Transfection o f PDGF-B chain over-expressing NIH3T3 cells with increasing
amounts o f the plasm id IkB67CJ clearly demonstrated the ability o f this plasmid not
only to express IicBa but also for this IicBa mutant to inhibit NF-kB activity in a dose
dependent manner (Figure 12). To determine the ability o f PDGF-B chain to induce
focus formation with these different constructs, NIH3T3 cells expressing the PDGF-B
chain were transfected with the IkB cc mutant (IkB67CJ) or an empty expression
vector (pRcCMV), the vector that was used to express the IkB67CJ, or the wild type
form o f p65 or the p65 mutant (p65AC) (Figure 13). Transfection o f NIH3T3 cells
with the mutant form o f hcBa (IkB67CJ) or the mutant form o f p65 (p65AC) and
PDGF-B chain resulted in significant inhibition (50% and 39% respectively) o f focus
formation when compared to focus formation in NTH3T3 cells that were transfected
with both PDGF-B chain and empty expression vector.
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Figure 12. Expression o f the Mutant o f ItcB Decreases NF- kB Activity in PDGF-B
Chain Over-expressing Cells.
PDGF-B chain over-expressing NIH3T3 cells were transfected with
increasing amounts o f plasmid that expressed the mutant form of IkB
(p MEIkB67CJ). A Western blot was performed on cell extracts (I kB
blot) using an anti-hcBa antibody. The reporter plasmid used in these
experiments contained the same promoter and NF- kB binding sequences
as in previous figures but used secreted alkaline phosphatase (SEAP)
instead o f luciferase as a reporter. Activation o f NF- kB by PDGF-B
(PDGF-B chain + p MEI kB67CJ Opg) was significantly greater than the
NF-kB activation in cells transfected with 5pg o f pMEhcB67CJ (PDGFB chain + p M EI kB67CJ 5pg) (p < 0.05, ANOVA and SNK tests). The
total amount o f plasmid transfected into PDGF-B chain over-expressing
NIH3T3 cells was equalized between samples by using the empty
expression vector pRcCMV.
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PDGF-B chain

PDGF-B chain
+pRcCM V

PDGF-B chain
+p65WT

PDGF-B chain
+pMEIicB67CJ

PDGF-B chain
+p65AC

pCDNA3.1 (-)

Number of Foci
PDGF-B chain
PDGF-B chain + pRcCMV
PDGF-B chain + p65WT
PDGF-B chain + pMEIicB67CJ
PDGF-B chain +p65AC
PCDNA3.1

11.2+1.0
12.7+1.8
8.25+0.9
6.3+0.6
7.75+0.5
1.25+0.3

Figure 13. Over-expression o f IkB and p65AC Inhibits Focus Formation in PDGF-B
Chain Over-expressing Cells.
NIH3T3 cells transfected with PDGF-B chain gene alone (PDGF-B
Chain). NIH3T3 cells transfected with the PDGF B chain gene and
pRcCMV vectors (PDGF-B chain + pRcCMV).
NIH3T3 cells
transfected with the PDGF-B chain gene and p65 wild type expressing
plasmid (PDGF-B chain + p65WT). NIH3T3 cells transfected with
PDGF-B chain gene and IkB mutant (PDGF-B chain +I kB67CJ).
NIH3T3 cells transfected with PDGF-B chain gene and p65AC (PDGF-B
chain +p65AC). NIH3T3 cells transfected with pCDNA3.1(-), the vector
used for expression o f the PDGF-B chain gene pCDNA3.1(-). In the
table above, number o f foci per cm2 is shown.
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Regulation o f NF-kB in Glioblastoma Cells

NF- kB Activity in U87-MG and U118-MG Cells

U87-MG and U118-MG glioblastoma cells have been shown to endogenously
express PDGF-B chain and the growth o f these cells is dependent on PDGF
expression and its autocrine loop (Chi et al., 1997; Kilic et al., 2000; Pollack et al.,
1990; Schilling et al., 1998). The cells have been shown to exhibit high NF-kB
activity (Murphy et al., 2001), thus they provide an ideal model to elucidate
secondary signaling molecules that mediate signaling between PDGF stimulation and
the regulation o f NF-kB activity. In our laboratory, the activity o f 8 transcription
factors in the glioblastoma cell lines U87-MG, U118-MG, U373-MG and a non
tumor derived cell line MCF10A were measured by 8 different reporter vectors
containing 4 tandem repeats o f consensus binding sequences for 8 different
transcription factors including NF-kB, A P-l, heat shock transcription factor - I (HSF1), ATF-2/CREB, GR, Elk-l/SRF, Myc, and NFAT.

In each reporter vector, 4

tandem repeats o f binding sequences for each transcription factor are followed by a
thymidine kinase promoter and a gene coding for secreted alkaline phosphatase
(SEAP).

Thus the amount o f SEAP activity in the medium should be directly

proportional to the amount o f transcription factor activity in the cells. The reporter
vectors were transfected into U87-MG, U118-MG, U373-MG and MCF10A cells.
The reporter vectors that contained binding elements for NF-kB, AP-l, HSF-1, ATF2/CREB, GR, Elk-l/SRF, Myc, and NFAT indicated activities o f HSF-1, ATF69
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2/CREB, GR, Elk-l/SRF, Myc, and NFAT transcription factors in the cells were low
and comparable to the control normal epithelial cell line MCF-IOA. On the other
hand, transfection o f the reporter vector for the NF-kB and AP-l transcription factors
exhibited significantly elevated levels o f SEAP activity in U87-MG and U118-MG
cells as compared not only to the control plasmid that lacked the NF-kB or AP-l
binding sequences (pTAL) but also to the glioblastoma cell line U373-MG and the
MCF-IOA control (Figure 14. Shimamura et al. manuscript submitted).
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Figure 14. NF-tcB is Activated in U87-MG and U118-MG but Not in U373-MG
Cells.
Cells were transfected as described in materials and methods. The
amount o f SEAP in the culture media was measured by adding substrate
and resultant fluorescent was measured in a fluorescent reader. Results
are the averages o f three independent experiments. Dark bar: pTAL
Shadowed bar: pNF-tcBSEAP.
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The results were confirmed with fluorescent electrophoretic mobility shift
assays (FEMSA) performed with nuclear extracts from U87-MG, U118-MG, U373MG and MCF-IOA.

Detectable amounts o f NF-icB binding to the fluorescently

labeled oligonucleotide containing the consensus NF- kB binding sequence were
observed in U87-MG, U l 18-MG, and U373-M G cells.

The same extracts were

incubated with an antibody directed against the human N F- kB p65 subunit to
determine if the binding was due to N F- k B .

Incubating lysates from U87-MG,

U l 18-MG, U373-MG with the antibody resulted in an apparent increase in molecular
weight o f the band (supershift), indicating the complex that was able to bind to the
consensus N F- kB binding sequence contained the NF- kB p65 subunit.

These

experiments demonstrated that N F- kB activity was present in all o f the extracts
except the MCF-IOA controls (Murphy et al., 2001).
Our laboratory has also shown that a truncated mutant o f the PDGFpR
interferes with the physiology o f the U87-M G and Ul 18-MG cells.

The mutant

PDGFpR lacks both kinase domains and many o f the tyrosine residues o f the
PDGFpR cytosolic domain that are essential in initiating receptor mediated secondary
signaling. Therefore, the truncated PDGFpR serves as a dominant negative mutant in
the cells.

U87-MG and Ul 18-MG cells were triple-transfected with wild-type or

truncated PDGFpR, NF- kB reporter vector, and P-galactosidase reporter plasmid.
SEAP activity was measured to assess NF- kB activity. The results were normalized
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with the specific activity o f demonstrated that NF- k B activity was significantly
decreased in the cells that expressed the truncated PD G FpR (data not shown).

Chemical Inhibitors o f PI3-K Influence NF-kB Activity

In order to demonstrate what pathways are involved in the signaling between
the PDGFpR and NF- kB, NF-kB gene reporter assays were performed in the
presence o f different chemical inhibitors including the PI3-K inhibitors LY294002
and Wortmannin, P44/42 Mitogen Activated Protein Kinase (MAPK) inhibitor
U0126, and p38 MAPK inhibitor SB203580. Among the chemical inhibitors, PI3-K
inhibitors only LY294002 and Wortmannin were able to suppress NF- kB activity in a
dose dependent manner (Figure 15).

Dominant Negative Mutant o f PI3-K Pathway Adapter Protein p85

In order to confirm that PI3-K pathway is involved in the signaling between PDGFpR
and NF-kB activation, a dominant negative mutant (DNM ) o f the p85a regulatory
subunit (Von Willebrand et al., 1996) was transfected into U87-MG and Ul 18-MG
cells and NF-kB activity was measured. The particular DNM used in this experiment
lacks the inter-SH2 domain in the C-terminus o f the protein, which is essential for the
p85 regulatory subunit activated by PDGFpR to bind to a p i 10 catalytic subunit o f
the PI3-K pathway.

Therefore the DNM o f the p 8 5 a regulatory subunit cannot

stimulate tyrosine p i 10 kinase subunit o f PI3-K pathway. The results indicated that
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this mutant was ineffective in inhibition o f NF- kB activity possibly due in part to low
expression o f the DNM (Figure 16).
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Figure 15. Chemical PI3-K Inhibitor to Suppress NF- kB Activity in U87-MG Cells.

(A) NF-tcB activity in U87-MG cells treated with OpM, 5pM, lOpM and
25pM o f LY294002 as indicated. (B) N F - kB activity in U87-MG cells
treated with OnM, 5nM, lOnM and 25nM o f Wortmannin as indicated.
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Figure 16. p85 Reguratory Subunit and NF-tcB Activity in U87-MG Cells
DNM o f p85 PI3-K regulatory subunit failed to suppress N F- kB activity
in U87 MG cells. Filled bar - NF-kB activity in U87-MG transfected
with vector control and control NF-kB reporter vector.
Bar with
holizontal lines - NF-kB activity in U87-MG transfected with vector
control and N F- kB reporter vectors. Shaded bar - NF- kB activity in
U87-MG transfected with wild type p85 and NF- kB reporter vectors. Bar
with dots —NF-kB activity in U87-MG transfected with DNM p85 and
NF-kB reporter vectors.
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Suppression of PI3-K p i 10 Iso form Expression in U87-MG

It has been shown that significant levels o f active PI3-K in U87-MG cells,
which was shown by the activity o f PDK.-1 (Flynn et al., 2000). In our laboratory, the
use o f PI3-K inhibitors on the cells exhibited significant morphological changes in the
cells which were quite evident under microscopic observation.
The

pi 10 catalytic

subunit is a

key molecule in PI3-K pathway

phosphorylating proteins and lipids in the cells. It is the kinase which LY294002
(Kovacsovics et al., 1995; Sanchez-Margalet et al., 1994; Vlahos et al., 1994) and
Wortmannin (Nakanishi et al., 1992; Okada et al., 1994a; Okada et al., 1994b) inhibit
to suppress PI3-K pathway activity in different cells. The p i 10 catalytic subunit o f
PI3-K. pathway therefore provides an ideal target for modulating the biological
activity o f PI3-K. pathway.
The p i 10 catalytic subunit includes four different isoforms; a , P, y, and
Among the isoforms, a , P, and

8

8

.

are known to associate with p85a regulatory subunit

and the y subunit is known to associate with plO l regulatory subunit in different
varieties o f cell types and seems to be regulated quite differently compared to a , P,
and

8

isoforms. Several reports indicate that the

8

isoform is abundant in leukocytes

(Domin & Waterfield, 1997; Vanhaesebroeck et al., 1997b), therefore

8

isoform is

most-likely absent in the cells o f astrocyte origin such as U87-MG and fibroblast
NIH3T3. Consequently, only the a and P isoforms among all four isoforms were
investigated in this study using siRNA.
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The experiments were designed to consider three potential problems. First, it
has been reported that delivering more than optimal amount o f siRNA sometimes
causes detrimental effects on the cells (Gura, 2000).

Second, using a suboptimal

amount o f siRNA may not be enough to silence the expression o f the target mRNA
and its expression. Third, the timing o f harvesting the cells after the transfection will
be critical as the silencing of protein expression by siRNA should be transient and the
silencing will wear o ff as time goes.
siRNAs against p i 10a and pllOP and control siRNAs were synthesized.
Transfected cells were harvested at 24, 32, and 48 hours post-transfection to find the
optimal time point o f suppression and cell lysates were collected. The lysates were
resolved on a SDS-PAGE followed by Western blot with anti-human p i 1 0 a or anti
human p i 10p antibody. It was found that the intensity o f the bands was decreased as
siRNA suppresses the endogenous expression o f p i 1 0 a and p i 10P (Figure 17).
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pi 10a ►

pllO P

►

Figure 17. siRNA Suppression o f p i 10 Expression.
Results from the Western blot performed on sample lysates from U87MG and U l 18-MG cells transfected with indicated amount o f p i 10a
siRNA and control siRNA.
SiRNA against p i 10a suppresses
endogenous expression o f pi 10a. The membrane was also blotted with
anti-NF-KB p65 subunit antibody as a control. (+ve) positive control:
EGF stimulated A 431 cell lysate.
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Suppression o f p i 10 a and B and PI3-K Pathway

After optimal dose and optimal harvesting time were determined for p i 10a
mRNA silencing by siRNA, activity o f PI3-K pathway in the U87-MG and U l 18-MG
cells was measured by using the Akt kinase assay described in Materials and
Methods.

The Akt kinase assay is based on the fact that both glycogen synthase

kinase-3 (GSK-3) a and P are substrates o f Akt kinase (protein kinase B and Bad
kinase) and are known downstream targets o f PI3-K pathway (Brady et al., 1998; K.
Datta et al., 1996; Franke et al., 1995; Hideshima et al., 2001). Threonine 308 and
serine 473 o f Akt kinase are known to be phosphorylated by 3-Phosphoinositidedependent kinase-1 (PDK- 1 ), which is activated by PI3-K. and PIP3 produced by PI3K. The active Akt kinase has been shown to phosphorylate serine 21 o f G SK -3a and
serine 9 o f GSK-3p. The anti-phospho-GSK-3 a /p serine 21/9 antibody is specific
and highly sensitive with near zero background.
Results show that significant PB -K activity was present in U87-MG cells
(Figure 18). The Akt kinase activity was reduced significantly in the U87-MG cell
lysates treated with siRNA against p i 10a and siRNA against pllOP in a dose
dependent manner. The result indicates that silencing p i 10a with siRNA in U87-MG
cells decreases the activity of PI3-K pathway in the cells.
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Figure 18. Inhibition o f PI3-K Activity by siRNA Against p i 10a and pi 10P
Results from the Akt Kinase assay performed on sample lysates from
U87-MG cells transfected with the indicated amounts o f pi 10a siRNA or
p i I Op siRNA and control siRNA.
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Suppression of pi 10 Iso forms and NF-kB Activity

Once the efficacy o f siRNA against PI3-K p i 10a and p i I0p to suppress PI3K pathway activity was verified, NF-icB activity in glioblastoma cell lines U87-MG
and Ul 18-MG transfected with pi 10 siRNA was measured by a reporter vector
containing a binding sequence for a transcription factor NF-icB. The reporter vectors,
optimal doses o f siRNAs, and vector coding for p- galactosidase were cotransfected
into U87-MG cells. The control plasmid that lacks the NF-icB binding sequences
(pTAL) was also used to measure the background noise o f the assay. The assay
results were normalized for specific activity o f p-galactosidase in order to take cell
density variability and the variability in transfection efficiencies among samples into
account.
The assay was carried out to determine if the PI3-K pathway plays essential
roles in controlling NF- kB activity in U87-MG cells. In theory, it was anticipated that
the activity o f a NF- kB was directly proportional to the activity o f PI3-K. pathway.
The inhibition o f p i 10 isoforms should result in the failure o f NF-kB activation as a
regulatory subunit IkB retains NF-kB in the cytoplasm.
Results from the assay showed that inhibition o f PI3-K pathway by 2 pg o f
siRNA against p i 10a and pllOP reduced NF- kB activity approximately 19% and
18% respectively in U87-MG (Figure 19 and 20).
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% NF-KB A ctyvlty

■ U87+0ug siRNA (Ctrl Reporter) B U87+0ug siRNA
D U87+NF+p110ctri siRNA 2ug
jS U87+NF+p110alpha siRNA lug D L^+N F+pH O alpha siRNA 2ug____________________________

Figure 19. Suppression o f NF-icB Activity by siRNA Against p i 10a
Results from NF- kB gene reporter assays with secreted alkaline
phosphatase (SEAP). Background noise o f the assay measured by pTAL
control reporter vector was subtracted from the SEAP activity obtained
for the lysates from each treatment. U87-MG cells treated with 2 fig o f
siRNA against p l l O a (U 87+NF+pll0asiRNA2) had 20% less NF-kB
activity than U87-MG cells transfected with the reporter vectors alone
(U87+NF).
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2348532353485348532323532353484848892353235323

■ U87+0ug siRNA (Ctrl Reporter) S U87+0ug siRNA

Z U87+NF+p110ctr1 siRNA 2ug

is U87-*-NF-vp110beta siRNA 1ug □ U87+NF+pn0beta siRNA 2ug____________________________

Figure 20. Suppression o f N F- kB Activity by siRNA Against p i 100
Results from NF- kB gene reporter assays with secreted alkaline
phosphatase (SEAP). The activity obtained with the pTAL control
reporter vector was subtracted from the SEAP activity obtained for the
lysates from each treatment. U87-MG cells treated with 2 pg o f siRNA
against pl lOP (U87+NF+pl lObeta siRNA 2ug) shows 19% less NF-kB
activity than U87-MG cells transfected with reporter vectors only
(U87+NF).
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FEMSA Assay Confirms the Inhibition o f NF- kB with siRNAs Against p i 10 a and B

Fluorescence electophoresis mobility shift assay (FEMSA) assay was
performed with nuclear extracts from U87-MG cells transfected with or without
siRNA against p i 10a and p i 10P (Figure 21). At 24 hours post-transfection, cells
were harvested and nuclear extracts were prepared. The amount o f NF- kB and its
binding capabilities were comparable between untreated (U87-MG) and U87-MG
cells transfected with control siRNA (U87-MG Ctrl siRNA). When the consensus
oligonucleotides were incubated with no nuclear extract (no EXT) there was no band.
When unlabeled NF- kB consensus oligonucleotides were added in excess to the
mixture o f nuclear extract and non-labeled consensus NF-kB oligonucleotides
(competition), the band indicating the binding o f NF- kB disappeared due to the
competition between labeled and unlabeled consensus NF-kB binding sequence to
bind NF-kB.

W hen the mixture was mixed with scrambled oligonucleotides, the

binding o f NF-kB to the NF- kB consensus oligonucleotide was present indicating the
specificity o f the NF- kB binding (Scramble). The amount of NF- kB and its binding
capabilities were decreased when U87-MG cells were treated with 2pg o f siRNA
against p i 10a and the amount of NF- kB and its binding capabilities were completely
abolished in U87-MG cells treated with 4 pg o f siRNA against p i 10a.
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No Extract
U87-MG
Scramble
Competition
p i 10a Control siRNA I2pg
pi 10a siRNA 6pg
pi 10a siRNA I2pg

pi 10p Control siRNA I2pg
p i i o g Control siRNA 6pg
p 110[3 Control siRNA 12pg
Figure 21. FEMSA Assay Performed with U87-MG Nuclear Extracts.
No Extract - No nuclear extract from U87-MG cells was mixed with
labeled NF-icB consensus oligonucleotide and complementary sequence.
U87-MG - Nuclear extract was mixed with labeled NF-icB consensus
oligonucleotide and complementary sequence.
Scramble - Nuclear
extract was mixed with labeled NF-tcB consensus oligonucleotide with
scrambled sequence and complementary sequence. Competition - No
nuclear extract was mixed with labeled NF-kB consensus oligonucleotide
and complementary sequence in the presence o f excess unlabeled NF-icB
consensus oligonucleotide. U87-MG Control siRNA - Nuclear extract
from U87-MG cells transfected with control siRNA was mixed with
labeled NF-icB consensus oligonucleotide and complementary sequence.
U87-MG siRNA p i 10a 6 pg - Nuclear extract from U87-MG cells
transfected with 6 pg o f siRNA against p i 10a was mixed with labeled
NF-tcB consensus oligonucleotide and complementary sequence. U87MG siRNA p i 10a 12pg - Nuclear extract from U87-MG cells
transfected with I2pg o f siRNA against p i 10a was mixed with labeled
NF-tcB consensus oligonucleotide and complementary sequence. An
arrow indicates binding o f NF-icB on consensus oligo nucleotides.
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NF-icB Activity in U87-MG Cells Transfected with Mutant PDGF Receptors

In order to demonstrate that PI3-K. pathway downstream o f PDGFPR is
responsible for controlling NF- kB activity, mouse fibroblast NIH3T3 cells were
stably transfected with pLXSN vectors containing wild type PDGFpR, F5Y PDGFPR
lacking five essential intracellular tyrosine residues, R634 PDGFPR whose lysine 634
residue essential for dimerization and auto kinase activity was replaced with arginine
(R634), F5Y PDGFpR whose intracellular 740/751 tyrosine residues were added
back (740), and F5Y PDGFpR whose intracellular 1009 tyrosine residues were added
back (1009) (Figure 22). Table 2 summarizes the effects o f the wild-type and mutant
PDGF receptors.

The cells stably expressing PDGFPR were established and the

overexpression of the receptors was confirmed by Western blot using anti-PDGFpR
antibody (Figure 23).
Gene reporter assays using SEAP were performed and the result indicated that
overexpressing PDGF P receptor in U87-MG cells increased NF-icB activity
compared to U87-MG cells without PDGF p receptor overexpressed (U87) except for
a cells transfected with R634 mutant (Figure 23). U87-MG cells transfected with
R634 mutant PDGF p receptor exhibited low NF-kB activity almost to the level of
the negative control (U87TAL). NF- kB activity in F5Y PDGF P receptor was lower
than the NF-icB activity in U87-MG cells transfected with wild-type PDGF P
receptor. When 740 and 751 intracellular tyrosine residues w ere added back to the
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F5Y (740), NF-icB activity was comparable to the one in U87-MG cells transfected
with wild-type PDGF P receptor.
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Figure 22. Design o f Wild Type and Mutant PDGF P Receptor.
WT - Wild type. R634 - Amino Acid Lysine 643 was replaced with
argine (R). F5Y - 5 tyrosine residues at positions 740/751/771/1009/1021
were replaced with Phenylalanine thus they cannot be phosphorylated
upon receptor dimerization. 740/751 - Among the 5 residues replaced to
phenylalanine, amino acids 740 and 751 were replaced (added back) to
tyrosine. This receptor can transduce signals downstream through PI-3K.
pathway as 740/751 phospho-tyrosine resides provide docking sites for
p85 regulatory subunit o f PI3-K pathway.
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Table 2
Mutations in Tyrosine Residues and Their Potential Effects on the Association o f
Secondary Signaling Molecules

mutanbnsTa#i:osiheresidues^
Wild Type
F5Y

R634
740/751
None

No mutation. A positive control
5 tyrosine residues
740/751/771/1009/1025 unable to activate
PI-3K, GAP, SHP-2, and PLC-y
Unable to carry out kinase activity (a
negative control)
Activates She, Nek, P1-3K, but not GAP,
SHP-2, and PLC-y
Vector only. Serves as a control
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■ U87-MG
JU 87-M G + PDGFpR WT
U87-MG + PDGFPR F5Y
U87-MG + PDGFpR 740/751
U87-MG + PDGFPR 1009
U87-MG + PDGFpR R634
Figure 23. Overexpression o f Wild Type and Mutant PDGF P Receptor.
Western blot analysis showing overexpression o f PDGF P receptor.
Whole cell lysates from untransfected U87-MG cells (U87-MG) and
U87-MG cells transfected with PDGF P receptors (WT, F5Y, 740/751,
1009, R634) were blotted using an anti-PDGFpR antibody.
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NF-kB Activity in U87-MG with m utant PDGFR

3.5

?i<yy»'yy
w ;5a /

S5£:S5»
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<t&2

1.5

05

:HDWT B F5Y □ R634 □ 1009 B 740 a U87 □ U87TAL
Figure 24. NF-tcB Activity in U87-MG Cells Transfected With Different PDGF p
Receptors.
WT - wild type PDGF p receptor, F5Y - PDGF P receptor lacking five
essential intracellular tyrosine residues, R634 - PDGF p receptor whose
lysine 634 residue essential for dimerization and auto kinase activity was
replaced with arginine (R634), 740 - F5Y PDGF P receptor whose
intracellular 740/751 tyrosine residues were added back , 1009 - F5Y
PDGF p receptor whose intracellular 1009 tyrosine residues were added
back. U87 - U87-MG cells transfected with empty vector and NF-icB
reporter vectors. U87TAL - U87-MG cells transfected with empty vector
and NF- kB control reporter vectors lacking NF- kB binging sequences.
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DISCUSSION

Activation o f NF- kB in PDGF-B Chain Transformed NIH3T3 Cells

Effects o f Acetvl Salicylic Acid

Receptor tyrosine kinases (RTKs) such as the PDGF receptors rely on the
intrinsic tyrosine kinase activities present in their cytoplasmic domains to transduce
stimulatory signals to the cell interior. PDGF receptors, like many other receptors,
activate multiple signaling cascades in a cell, not all o f which may play a role in the
myriad o f responses to PDGF.

In an effort to determine the pathways that are

necessary for transformation o f cells by PDGF, we used ASA to study the effects on
the ability o f PDGF to form foci and stimulate mitogenesis.
The results presented here demonstrate that ASA and SA can effectively
inhibit PDGF stimulated focus formation. Both ASA and SA have several known
functions within cells.

Both can irreversibly acetylate both iso forms o f PGHS

(Bhattacharyya et al., 1995; Mancini et al., 1997; Roth et al., 1983) causing a
reduction in the synthesis o f prostaglandins that eventually leads to inhibition o f DNA
synthesis stimulated by PDGF (Castano et al., 1997; Shier & Durkin, 1982). ASA
can also inhibit cell growth by inhibiting KK.-P which results in a decrease in
activation o f NF-kB (Yin et al., 1998).
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Prostaglandins and Tumor

Prostaglandin synthesis regulated by COX2 (PGHS2) has been drawing the
attention o f researchers as recent studies suggest that COX-2-derived prostaglandins
may play a pivotal role in the maintenance o f tumor viability, growth, and metastasis
(Attiga et al., 2000; Crew et al., 2000; Fosslien, 2000; Murata et al., 1999; Williams
et al., 1999). To determine if the inhibition o f prostaglandin synthesis is the reason
for ASA's ability to inhibit focus formation in PDGF-B chain transformed cells, cells
were treated with NS398 and indomethacin, NSAIDs known to inhibit PGHS2 but
not NF-kB. Unlike ASA, neither o f these had a significant effect on PDGF induced
focus formation at concentrations known to inhibit PGHS2.

At elevated

concentrations (above 20mM), NS398 inhibited PDGF-induced focus formation but
these concentrations are much higher than concentrations reported to completely
inhibit PGHS2 (less than lOmM) (Attiga et al., 2000; Q. Guo et al., 1996). Similarly,
the addition o f PGEi, the primary prostaglandin produced upon PDGF stimulation o f
cells and the prostaglandin capable of restoring PDGF induced DNA synthesis after it
has been blocked by ASA, had no effect on restoring PDGF induced focus formation.
It has been reported that glioma cells with a higher rate o f cell proliferation tend to
have increased expression o f COX-2 (Prayson et al., 2002).

In our laboratory,

treating glioma cells such as U87-MG and U118-MG with high concentration o f ASA
had no effect on NF-kB or AP-1 activity (data not shown). The evidence suggests
that the involvement o f COX-2 in tumor growth and development may depend on cell
types.
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NF-kB and Glioblastomas

Inhibition o f NF- kB activation by a dominant negative mutant o f IkB cx or a
dominant negative form o f p65 that lacks c-terminus transactivation domain could
effectively inhibit PDGF induced focus formation, indicating that the inhibition o f
focus formation by ASA was probably due to its inhibition o f activation o f NF- kB.
The EMSA results clearly indicated that the DNA binding capability o f NF- kB in
PDGF-B chain over-expressing fibroblasts was significantly reduced under ASA
treatment and that N F- kB promoter activity also decreased in the presence o f ASA.
NF-kB is a transcription factor that regulates the expression o f a variety o f
cellular genes (Perkins et al., 1992). It has been reported that NF-kB is involved in
focus formation by the Ha-ras, abl, and Her2/neu oncogene (T. S. Finco et al., 1997;
Pianetti et al., 2001; Reuther et al., 1998). It has been known that NF-kB activity is
increased in some breast tumors, glioblastomas, and non-Hodgkins lymphomas (T. S.
Finco et al., 1997; Murphy et al., 2001).
Although it is not known how exactly NF-kB contributes to tumor formation,
several reports have indicated that NF-kB can stimulate the expression o f the Cyclin
D1 gene and that this is a central feature o f movement from G1 into S phase
(Guttridge et al., 1999; Hinz et al., 1999). It remains unclear whether the NF-kB
mediated Cyclin D1 gene expression is necessary for its ability to stimulate focus
formation in cells.
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PI3-K Pathway and the Regulation o f NF-icB in PDGF Stimulated NIH3T3 Cells

It has been reported that PDGF may stimulate NF-kB through the activity o f
PI-3K (Olashaw et al., 1992; Romashkova & Makarov, 1999). We have not observed
decreased NF-kB activity in NIH3T3 cells expressing both dominant negative
mutants o f the p85 PI-3K regulatory subunit and PDGF-B chain or in NIH3T3 cells
over-expressing PDGF-B chain treated with drugs that inhibit PI-3K activity (data not
shown). Similarly, by using PDGF receptor mutants incapable o f signaling through
PI-3K, we have not obtained results that indicate PI-3K is necessary for NF-kB
activation in CHO cells (data not shown). This results somewhat corresponds to the
observation that radiation induced NF-kB activity in human ovarian carcinoma is
inhibited by adenovirus type 5 El A expression and inhibition is not mediated by the
PI-3k downstream molecule Akt but by the inhibition o f IkB degradation (Shao et al.,
1997; Shao et al., 2001). In contrast to these results, transformation o f NIH3T3 cells
with the retroviral oncogene p3k (v-p3k) of avian sarcoma virus 16 (ASV16) that
codes the catalytic subunit o f phosphoinositide (PI) 3-kinase (Chang et al., 1997),
resulted in increased activity o f NF-kB (data not shown). This conflicting evidence
indicates that the induction o f NF-kB activity by PDGF m ay involve complex cellular
mechanisms that require multiple secondary signaling pathways responsible at
various steps in cellular transformation. In addition, the involvement of the PI-3K
pathway in PDGF-B chain mediated NF-kB may well be dependent on the cell lines
used.
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Possible Involvement o f Transcription Factor AP-1

It has been demonstrated that ASA also inhibits the induction o f activator
protein-1 (A P -l) (Huang et al., 1997) and that AP-1 activation may be necessary for
transformation induced by PDGF, TP A, and TNF (J. J. Li et al., 1997; Mercola et al.,
1988) and in neoplastic progression in human papillomavirus (HPV) immortalized
human keratinocytes (J. J. Li et al., 1998). Although our results do not exclude a role
for ASA inhibition o f AP-1 in the suppression o f PDGF induced transformation of
NTH3T3 cells, it is clear that NF-kB also must play a role.

Regulation o f NF- kB in Glioblastoma Cells

NF- kB Activity in U87-MG and U118-MG Cells

U87-MG glioblastoma (astrocytoma) cells were chosen as models to study the
PDGF mediated tumorigenecity, primarily because the cells were known to
overexpress PDGF B chain and exhibited significantly higher NF- kB activity
compared to U373 glioblastoma cells and normal epithelial cell MCF-10 (Figure 14).
Results presented here strongly suggest that PDGFpRs play an essential role for
regulating N F- kB activity in U87-MG glioblastoma cells as indicated by the
experiments using kinase-deficient PDGFpR (R634) which significantly decreased
NF-kB activity in these cells (Figure 24). In addition, introducing truncated PDGFpR
into U87-MG cells with resulted in significant growth inhibition and reduced NF- kB
activity (data not shown).
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PI3-K Pathway and NF-icB Activity in U87-MG Cells

In order to elucidate the secondary signaling molecules responsible for
mediating signals from PDGF P receptor to NF-kB in U87-MG cells, NF-kB gene
reporter assays were performed in the presence o f different concentrations o f
chemical inhibitors including the PI3-K inhibitors LY294002 and Wortmannin,
P44/42 Mitogen Activated Protein Kinase (MAPK) inhibitor U0126, and p38 MAPK
inhibitor SB203580.

Among the chemical inhibitors, only PI3-K inhibitors

LY294002 and Wortmannin were able to suppress N F- kB activity in a dose
dependent manner (Figure 15).
Based on the results obtained from the use o f PI3-K inhibitors, the hypothesis
that the activity o f a transcription factor NF- kB is under the regulation by PDGF
mediated PI3-K pathway activity was tested.
A dominant negative mutant o f p85 PI3-K regulatory subunit (p85AiSH2) that
is unable to bind to the p i

10

catalytic subunit and therefore unable to mediate signals

from the PDGF receptor to the p i 10 catalytic subunit o f PI3-K was used to inhibit
PI3-K pathway activity. The use o f p85AiSH2 did not suppress NF-kB activity as
anticipated (Figure 16).

There seems to be two possible explanations for these

results. First, the expression o f p85 dominant negative mutant may have not been
enough to overcome the intrinsic expression o f p85 in U87-MG cells. It has been
known that an over-saturating amount o f dominant negative protein is sometimes
necessary to overcome the endogenous expression o f a target protein. It was very
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difficult to verify overexpression o f wild-type pS5 and p85AiSH2 by Western blot, as
a molecular weight difference between p85 wild-type and p85AiSH2 was not large
enough to be resolved on a gel. Second, it is possible that NF-kB activity in U87-MG
cells is regulated by PI3-K pathway activity independent o f an interaction between
p85 regulatory subunit and p i 10 catalytic subunit. PDGF B chain binding o f
PDGFPRs results in the association o f multiple secondary signaling molecules (Table
I), which include RasGAP (Rodriguez-Viciana et al., 1994) known to associate and
independently stimulate the p i

10

catalytic subunit to initiate lipid kinase activity.

Moreover, it has been reported that some tissue samples isolated from p85a knockout
mouse exhibited high PI3-K activity (Suzuki et al., 1999; Terauchi et al., 1999).
PI3-K inhibitors W ortmannin and LY294002 are known to inhibit not only the
activity o f p i 10 catalytic subunit o f PI3-K. pathway but also the activity other kinases
including phosphatidylinositol 4 kinase that may potentially provide supplemental
roles to the functionality o f PI3-K pathway (Sorensen et al., 1998; Wong & Cantley,
1994).

p i 10 Suppression by siRNA and PI3-K Activity

Both Wortmannin and LY294002 are known to inhibit the catalytic activity o f
p i 10 subunit of PI3-K pathw ay (Sanchez-Margalet et al., 1994; Ui et al., 1995;
Vlahos et al., 1994), but their specificity for the pi 10 isoforms are not known. Based
on the finding that inhibition o f p85 reguratory subunit o f P13-K. pathway does not
decrease NF-kB activity in U87-M G cells, selective inhibition o f the p i 10 catalytic
99
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subunit gene was considered to inhibit the activity o f PI3-K and subsequent
regulation o f NF-icB. The p i 10 catalytic subunit includes four different iso forms, a ,
P, y, and 8 . Among the four p i 10 isoforms, a and P isoforms were chosen for targets
for inhibition mainly due to the fact that the two iso forms are known to be most
catalytically active among the four isoforms (Beeton et al., 2000).

The use o f a

dominant negative mutant p i 10a (kinase deficient) called pllO a-C A A X has been
described, but it was concluded that stability o f the pllO a-C A A X could not be
guaranteed without expressing the dominant negative mutant together with p85
regulatory subunit (Rodriguez-Viciana et al., 1994). In addition, the unavailability o f
pllOP dominant negative mutant forced us to stay away from the use o f dominant
negative mutant.
RNA interference by short interfering RNA (siRNA) is a relatively new
technique that utilizes double stranded RNA o f 21 nucleotides in length to inhibit
gene expression. The double stranded RNA corresponds to exon sequences in the
mRNA and suppresses gene expression o f the target gene be degrading mRNA much
more efficiently than anti-sense RNA.
The experiments described above were designed to consider two important
parameters; 1) optimal amount o f siRNA and 2) the timing to harvest the cells after
the transfection.

It seemed that maximal suppression o f pi 10a and pl lOP protein

expression took place at 24 hrs post-transfection, though the inhibition o f target
protein expression by siRNAs observed at the time point was not 100%. Testing the
expression o f p i 10 catalytic subunit by Western blot was extremely difficult due in
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part to the lack o f good immunoblotting antibodies against p i 10a and p i I0p. Two
different kinds o f antibodies were used for each p i

10

isoform with unsatisfactory

results. Apparently, this problem has been confirmed by others as well (Bi et al.,
1999).

Immunoprecipitations by antibodies against each p i 10 iso form were

absolutely necessary to capture enough p i 10 to resolve on an acrylamide gel (Figure
17). Although Western blot is an ideal method to detect the suppression o f gene
expression by siRNA, quantitative RT-PCR may be necessary to detect and measure
mRNA degradation.
In spite o f the weak inhibition o f pi 10 expression, the introduction o f siRNA
targeting p i 10 iso forms resulted in reduction o f PI3-K activity measured by Akt
kinase assay (Figure 18), but further testing by using densitometry must be performed
to verify the results.
The results presented here point out the fact that important parameters need to
be worked out in the future for the implementation o f siRNA technique. Series o f
new techniques are emerging to better implement the robustness o f gene silencing by
siRNA.

Initially, it was believed that targeting 5 ’ end o f the target mRNA is

sufficient to degrade target mRNA, but it seems that it is not always the case.
Growing evidence suggests that it is better to design multiple siRNAs that target
different locations o f a target mRNA. Yang et al. recently reported that Escherichia
coli RNase III could be used to cleave long double-stranded RNA (dsRNA) into
endoribonuclease-prepared siRNA (esiRNA) that can target multiple sites within an

101

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

mRNA (Yang et al., 2002). Apparently, esiRNA is much more effective than using
one siRNA to silence a target mRNA (Yang et al., 2002).
It needs to be mentioned that the duration o f gene silencing effect by siRNA
has not been fully elucidated. If siRNA is used against a protein with high turnover,
the amount o f siRNA used must be increased proportionally. Due to the lack o f a
system to deliver large quantity o f siRNA without disrupting the physiological
stability o f the cell, it seems to be very difficult to suppress protein with a high
turnover.

The p i 10 molecule studied here may fall under the category o f high-

tumover protein. Expressing short siRNA duplexes within cells from recombinant
DNA constructs has been proposed, because it allows long-term target-gene
suppression in cells (Brummelkamp et al., 2002; Paul et al., 2002).

p i 10 Suppression by siRNA and NF-icB Activity

Although the use o f siRNA against p l l Oa and pl l Op managed to decrease
PI3-K activity in U87-MG cells as measured by Akt kinase assay (Figure 18). Gene
reporter assay (Figure 19 and 20) showed that the reduction in N F- kB activity caused
by pi 10a siRNA and pllOP siRNA treatments was 20 % and 19% respectively,
which was not statistically significant.
The discrepancy between those results and results obtained with chemical
inhibitors could be due to several reasons.

Inhibiting p i 10 catalytic subunit with

siRNA may be quite different from inhibition o f PI3-K pathway with chemical
inhibitors. As mentioned earlier, the chemical inhibitors Wortmannin and LY294002
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may have yet unknown side effects in the cells. Thus just inhibiting p i 10 iso forms
might fail to fully suppress PI-3K pathway as the inhibition may inadvertently
activate other signaling molecules that can supplement PI3-K activity and modulate
NF-icB activity.

The p85 regulatory subunit o f PI3-kinase has been reported to

specifically associate with tyrosine-phosphorylated IicBa through its Src homology 2
(SH2) domains in vitro and in vivo after stimulation o f T cells with pervanadate
(Beraud et al., 1999). This might have resulted in NF-kB activation. It has been
shown that cdc42 could directly associate with p85. Although cdc42 does not seem
to directly activate NF-kB, cdc42 is known to interact with guanidine nucleotide
exchange factors and proteins with PH domains that are known to modulate NF-kB
activity (Korus et al., 2002). Thus it is possible for cdc42 to indirectly stimulate NFkB

activity.
In addition, though the PI3-K pathway plays significant roles in controlling

NF-kB in the cells, PI3-K pathway may not be the only pathway to regulate NF-kB
activity.

The presence of other pathways besides PI3-K. pathway downstream o f

PDGF receptor to activate NF-kB may substitute the roles normally played by PI3-K
pathway as well.
It is also possible that the SEAP gene reporter assay might fail to accurately
report NF- kB activity. Accumulation o f SEAP in the medium usually takes 48 hours
post-transfection to be optimal and detectable. As the inhibition o f PI3-K pathway by
pi 10a siRNA and p i 10P siRNA seemed to be at its best at 24 hrs post-transfection,
PI3-K activity might slowly return to normal during the 24-48 hour time period
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(Figure 8 . Gray area below parabola 24hrs to 48 hours). The increase in p i 10a and
pllOp production and subsequent increase in PI3-K activity might be sufficient for
the activation of NF-kB and production o f SEAP, which might accumulate during the
24-48 hours time period. The siRNA mediated silencing o f mRNA was transient,
which means that the inhibition could wear off as time goes. SEAP assay measures
accumulation of SEAP in the medium, therefore the incomplete inhibition o f p i 10a
and p i 10P may hinder the suppression o f SEAP production (i.e. inhibition o f NF-kB)
achieved at 24 hour time point. Same situation could be true to the period where
siRNA starts to inhibit p i 10a and pllOP (Figure

8

. Gray area below parabola 0-24

hours time point). During this period, one would assume PI3-K activity was present
and sufficient enough to cause the activation o f NF-kB and production o f SEAP,
which might be accumulated during the 0-24 hours time period.
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a.
©
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Time

Figure 8 .

p i 10 Inhbibition by siRNA.
siRNA is known to suppress the target gene between 24 to 48 hour post
transfection in mammalian cells (Elbashir et al., 2001a). In this diagram,
p l l Oa siRNA is shown to maximally suppress p i 10a expression at 24
hours post transfection. PI3-K. activity still exists before and after the
maximal suppression by siRNA, which may be enough for NF-kB to be
actively inititate transcription.
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EMSAs were also performed to determine the effect o f PI3-K pathway on the
regulation o f NF-icB activity. By harvesting nuclear protein at 24 hour from the cells
treated with siRNA against the p i 10 catalytic subunit o f PI3-K. the most significant
reduction in NF-tcB binding should be evident.

It was hypothesized that PI3-K.

activity was the lowest at 24 hours post transfection with siRNA as suppression by
siRNA against p i 10a and pllO P should be the greatest at the time.

The result

presented (Figure 21) shows that binding o f NF-tcB was not significantly altered by
the treatment o f the cells with siRNA against pi 10a or p iI0 p .

Regulation o f NF-tcB Activity by PDGF

Although this study attempted to focus on the roles o f PI3-K. activity in the
regulation of NF-tcB in glioblastoma U87-MG cells, what this study actually revealed
was the complex regulation o f transcription factor NF-tcB by PDGF p receptors. The
results obtained from gene reporter assays in U87-MG cells transfected with wildtype and mutant PDGF P receptors are statistically insignificant, but it was a quite
surprise to discover that R634 mutant (kinase deficient mutant) o f PDGF P receptors
significantly suppressed NF- kB activity in U87-MG cells almost to the background
level. This result strongly suggests that PDGF P receptor plays pivotal role in the fate
o f NF- kB and U87-MG glioblastoma cells. On the contrary, it was a quite surprise to
know that add-back mutants 1009 and 740/751 are capable o f activating NF- kB as
wild-type (Figure 24). Considering the fact that U87-MG cells transfected with the
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F5Y mutant and, secondary signaling molecules that associate with tyrosine 1009,
740, and 751 are capable o f turning on signaling cascade leading to the activation NFkB.

Overall, the results obtained from this study points out that transcription factor
NF- k B plays an essential roles in PDGF mediated cellular transformation. Secondary
signaling cascades that connect PDGF receptor activation and NF- kB seem to be very
complex.

Not much has been known for crosstalks between signaling cascades,

which make signal transduction a complex process.

107

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Appendix A
Permission to Use Contents From
Experimental Cell Research, 274(1): 157-167, 2002
Elsevier Science

108

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

July 25,2002
Takeshi Shimamura
Department o f Biological Sciences
Western Michigan University
1903 W. Michigan Avenue
Kalamazoo, MI 49008-5410
Re: "Activation o f NF-lcappaB is required for PDGF-B chain to transform NIH3T3 cells” by
Takeshi Shimamura, from Experimental Cell Research, Volume 274,157-67, copyright 2002,
Elsevier Science (USA), reprinted with permission from the publisher.
Dear Takeshi Shimamura:

PERMISSION GRANTED to include the above-referenced material, in your
thesis/dissertation and to print up to 200 copies provided that 1) complete credit is given to the
source, including the appropriate copyright notice. All rights reserved.; 2) the material to be
used has appeared in our publication without credit or acknowledgment to another source and 3)
if commercial publication should result, you must contact the publisher again.
We realize that University of Microfilms or national Library o f Canada must have permission to
sell copies o f your thesis, and we agree to this. However, we must point out that we are not
giving permission for separate sale o f your article.
Sincerely,

Paralegal
Academic Press-Permissions

E lic v ic r S cien c e (U SA) 6 2 7 7 Sea H a rb o r D rive. O ria n d o . FL J28S7-4SOO. USA
Tel .1 (407) 345 2 0 0 0 | Fax • I (4 0 7 ) 34 5 4 0 5 8 [ www .elievicr.com

Aeudemic Press • Bunenoarth-Heinemesnrt • Cell Prrss • Churchill Livinptorse • Ertp'neering ta/ormxeiors • Excerptit Mertica
The Lxncet * M DConmle • M DL • Masby * North-H alland • Perptmon * ScimceDirect • W B SaunJen

109

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

BIBLIOGRAPHY

Alberts, B. (1994). Molecular biology o f the cell (3rd ed.). New York: Garland Pub.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., &
Hemmings, B. A. (1996). Mechanism o f activation o f protein kinase B by
insulin and IGF-1. Embo J. 75(23), 6541-6551.
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C.
B., & Cohen, P. (1997). Characterization o f a 3-phosphoinositide-dependent
protein kinase which phosphorylates and activates protein kinase Balpha. Curr
Biol, 7(4), 261-269.
Arvidsson, A.-K., Rupp, E., Nanberg, E., Downward, J., Ronnstrand, L., Wennstrom,
S., Schlessinger, J., Heldin, C.-H., & Claesson-Welsh, L. (1994). Tyr-716 in
the platelet-derived growth factor b-receptor kinase insert is involved in
GRB2 binding and ras activation. Mol. Cell. Biol., 14, 6715-6726.
Attiga, F. A., Fernandez, P. M., Weeraratna, A. T., Manyak, M. J., & Patiemo, S. R.
(2000). Inhibitors o f prostaglandin synthesis inhibit human prostate tumor cell
invasiveness and reduce the release o f matrix metalloproteinases. Cancer Res,
60(16), 4629-4637.
Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X. J., Miralpeix,
M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., & et al. (1992).
Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during
insulin stimulation. Embo J, 7/(9), 3469-3479.
Bae, Y. S., Cantley, L. G., Chen, C. S., Kim, S. R., Kwon, K. S., & Rhee, S. G.
(1998). Activation o f phospholipase C-gamma by phosphatidylinositol 3,4,5trisphosphate. J Biol Chem, 273(8), 4465-4469.
Baeuerle, P. A. (1991). The inducible tmascription activator NF-kB: regulation by
distinct protein subunits. Biochem. Biophys. Acta, 1072, 63-80.
Bargmann, C. I., Hung, M. C., & Weinberg, R. A. (1986a). Multiple independent
activations o f the neu oncogene by a point mutation altering the
transmembrane domain o f p i 85. Cell, 45(5), 649-657.

110

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Bargmann, C. I., Hung, M. C., & Weinberg, R. A. (1986b). The neu oncogene
encodes an epidermal growth factor receptor-related protein. Nature,
5/9(6050), 226-230.
Bauer, E. A., Cooper, T. W., Huang, J. S., Altman, J., & Deuel, T. F. (1985).
Stimulation o f in vitro human skin collagenase expression by platelet- derived
growth factor. Proc Natl Acad Sci U S A , 52(12), 4132-4136.
Beeton, C. A., Chance, E. M., Foukas, L. C., & Shepherd, P. R. (2000). Comparison
o f the kinetic properties of the lipid- and protein-kinase activities o f the
pllO alpha and pllO beta catalytic subunits o f class-Ia phosphoinositide 3kinases. Biochem J, 350 Pt 2, 353-359.
Beg, A. A., & Baltimore, D. (1996). An essential role for NF-kappaB in preventing
TNF-alpha-induced cell death. Science, 274(5288), 782-784.
Bejcek, B. E., Li, D. Y., & Deuel, T. F. (1989). Transformation by v-sis occurs by an
internal autoactivation mechanism. Science, 245, 1496-1499.
Beraud, C., Henzel, W. J., & Baeuerle, P. A. (1999). Involvement o f regulatory and
catalytic subunits o f phosphoinositide 3-kinase in NF-kappaB activation. Proc
Natl Acad Sci U S A , 96(2), 429-434.
Bergsten, E., Uutela, M., Li, X., Pietras, K., Ostman, A., Heldin, C. H., Alitalo, K., &
Eriksson, U. (2001). PDGF-D is a specific, protease-activated ligand for the
PDGF beta- receptor. Nat Cell Biol, 5(5), 512-516.
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001). Role for a
bidentate ribonuclease in the initiation step o f RNA interference. Nature,
409(6818), 363-366.
Berridge, M. J. (1993). Inositol trisphosphate and calcium signalling. Nature,
56/(6410), 315-325.
Betsholtz, C., Johnsson, A., Heldin, C. H., Westermark, B., Lind, P., Urdea, M. S.,
Eddy, R„ Shows, T. B., Philpott, K„ Mellor, A. L., & et al. (1986). cDNA
sequence and chromosomal localization o f human platelet-derived growth
factor A-chain and its expression in tumour cell lines. Nature, 520(6064), 695699.
Bhat-Nakshatri, P., Sweeney, C. J., & Nakshatri, H. (2002). Identification o f signal
transduction pathways involved in constitutive NF-kappaB activation in breast
cancer cells. Oncogene, 2/(13), 2066-2078.
Ill

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Bhattacharyya, D. K., Lecomte, M., Dunn, J., Morgans, D. J., & Smith, W. L. (1995).
Selective
inhibition
of
prostaglandin
endoperoxide
synthase-1
(cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys, 317(1),
19-24.
Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., & Nussbaum, R. L. (1999).
Proliferative defect and embryonic lethality in mice homozygous for a
deletion in the pllO alpha subunit o f phosphoinositide 3-kinase. J Biol Chent,
274( 16), 10963-10968.
Bonthron, D. T., Morton, C. C., Orkin, S. H., & Collins, T. (1988). Platelet-derived
growth factor A chain: gene structure, chromosomal location, and basis for
alternative mRNA splicing. Proc Natl Acad Sci U S A , 85(5), 1492-1496.
Brady, M. J., Bourbonais, F. J., & Saltiel, A. R. (1998). The activation o f glycogen
synthase by insulin switches from kinase inhibition to phosphatase activation
during adipogenesis in 3T3-L1 cells. J Biol Chem, 273(23), 14063-14066.
Bronzert, D. A., Pantazis, P., Antoniades, H. N., Kasid, A., Davidson, N., Dickson, R.
B., & Lippman, M. E. (1987). Synthesis and secretion o f platelet-derived
growth factor by human breast cancer cell lines. Proc. NAt. Acad. Sci. USA,
84?, 5763-5767.
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002). A system for stable
expression o f short interfering RNAs in mammalian cells. Science, 296(5561),
550-553.
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J.,
Arden, K. C., Blenis, J., & Greenberg, M. E. (1999). Akt promotes cell
survival by phosphorylating and inhibiting a Forkhead transcription factor.
Cell, 96(6), 857-868.
Bundy, D. L., & McKeithan, T. W. (1997). Diverse effects o f BCL3 phosphorylation
on its modulation o f NF-kappaB p52 homodimer binding to DNA. J Biol
Chem, 272(52), 33132-33139.
Burgering, B. M., & Coffer, P. J. (1995). Protein kinase B (c-Akt) in
phosphatidylinositol-3-OH kinase signal transduction. Nature, 376(6541),
599-602.

112

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Bywater, M., Rorsman, F., Bongcam-RudlofF, E., Mark, G., Hammacher, A., Heldin,
C.-H., Westermark, B., & Bestholtz, C. (1988). Expression o f recombinant
platelet-derived growth factor A- and B-chain homodimers in rat-1 cells and
human fibroblasts reveals differences in protein processing and autocrine
effects. Mol. Cell. Biol., 8, 2753-2762.
Cao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V., &
Karin, M. (2001). IKKalpha provides an essential link between RANK
signaling and cyclin D1 expression during mammary gland development.
Cell, 707(6), 763-775.
Caplen, N. J., Parrish, S., Imani, F., Fire, A., & Morgan, R. A. (2001). Specific
inhibition o f gene expression by small double-stranded RNAs in invertebrate
and vertebrate systems. Proc Natl Acad Sci U S A , 98(17), 9742-9747.
Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B.,
Shoelson, S., & Cantley, L. C. (1993). Phosphoinositide 3-kinase is activated
by phosphopeptides that bind to the SH2 domains o f the 85-kDa subunit. J
Biol Chem, 268(13), 9478-9483.
Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G. (1996).
The TEL/platelet-derived growth factor b receptor (PDGFbR) fusion in
chronic myelomonocytic
leukemia is a transfroming protein that self
associates and activates PDGFbR kinase-dependent signaling pathways. Proc.
Nat. Acad. Sci. USA, 93, 14845-14850.
Castano, E., Dalmau, M., MArti, M., Berrocal, F., Bartrons, R., & Gil, J. (1997).
Inhibition o f DNA synthesis by aspirin in Swiss 3T3 fibroblasts. J. Pharm.
Exp. Ther., 280(1), 366-372.
Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Ballacosa, A., Tsichlis, P. N.,
Cantley, L. C., Roberts, T. M., & Vogt, P. K. (1997). Transformation o f
chicken cells by the gene encoding the catalytic subunit o f PI 3-kinase.
Science, 276, 1848-1850.
Chi, K. D., McPhee, R. A., Wagner, A. S., Dietz, J. J., Pantazis, P., & Goustin, A. S.
(1997). Integration o f Proviral DNA into the PDGF beta-receptor gene in
HTLV-I-infected T-cells Results in a Novel Tyrosine Kinase Product with
Transforming Activity. Oncogene, 15, 1051-1057.
Chin, L. S., Murray, S. F., Zitnay, K. M., & Rami, B. (1997). K252a inhibits
proliferation o f glioma cells by blocking platelet-derived growth factor signal
transduction. Clin Cancer Res, 3(5), 771-776.
113

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Choudhury, G. G., Marra, F., Kiyomoto, H., & Abboud, H. E. (1996). PDGF
stimulates tyrosine phosphorylation o f JAK 1 protein tyrosine kinase in
human mesangial cells. Kidney Int, 49( 1), 19-25.
Clark, J. G., Madtes, D. K., & Raghu, G. (1993). Effects o f platelet-derived growth
factor isoforms on human lung fibroblast proliferation and procollagen gene
expression. Exp Lung Res, 19(3), 327-344.
Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., & Baldwin, A. S. J. (2000).
Selective activation o f NF-kB subunits in human breast cancer: potential roles
for NF-kB2/p52 and BcI-3. Oncogene, 19, 1123-1131.
Collins, T., Bonthron, D. T., & Orkin, S. H. (1987). Alternative RNA splicing effects
function o f encoded platelet-derived growth factor A chain. Nature, 3328,
621-624.
Collins, T., Ginsburg, D., Boss, J. M., Orkin, S. H., & Pober, J. S. (1985). Cultured
human endothelial cells express platelet-derived growth factor B chain: cDNA
cloning and structural analysis. Nature, 316(6030), 748-750.
Conte, E., Bonaiuto, C., Nesci, C., Crimi, N., Vancheri, C., & Messina, A. (1997).
Nuclear factor-kappaB activation in human monocytes stimulated with
lipopolysaccharide is inhibited by fibroblast conditioned medium and
exogenous PGE2. FEBS Lett, 400(3), 315-318.
Crew, T. E., Elder, D. J., & Paraskeva, C. (2000). A cyclooxygenase-2 (COX-2)
selective non-steroidal anti-inflammatory drug enhances the growth inhibitory
effect o f butyrate in colorectal carcinoma cells expressing COX-2 protein:
regulation o f COX-2 by butyrate. Carcinogenesis, 2/(1), 69-77.
Datta, K., Bellacosa, A., Chan, T. O., & Tsichlis, P. N. (1996). Akt is a direct target
o f the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and
v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem, 271(48), 30835-30839.
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E.
(1997). Akt phosphorylation o f BAD couples survival signals to the cellintrinsic death machinery. Cell, 91(2), 231-241.
De Jong, J., Van Deist, P. J., Van Der Valk, P., & Baak, J. P. A. (1998). Expression
o f growth factors, growth-inhibiting factors, and their receptors in invasive
breast cancer. II: correlations with proliferation and angiogenesis. J. Path.,
184, 53-57.

114

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Dechend, R., Hirano, F., Lehmann, K., Heissmeyer, V., Ansieau, S., Wulczyn, F. G.,
Scheidereit, C., & Leutz, A. (1999). The Bcl-3 oncoprotein acts as a bridging
factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene, 18(22),
3316-3323.
del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., & Nunez, G. (1997).
Interleukin-3-induced phosphorylation o f BAD through the protein kinase
Akt. Science, 278(5338), 687-689.
DeMali, K. A., Whiteford, C. C., Ulug, E. T., & Kazlauskas, A. (1997). Plateletderived Growth Factor-dependent Cellular Transformation Requires Either
Phospholipase Cgamma or Phosphatidylinositol 3 Kinase. Journal o f
Biological Chemistry, 272(14), 9011-9018.
Deuel, T. F. (1988). Polypeptide growth factors: roles in normal and abnormal cell
growth. Ann. Rev. Cell Biol., 3, 443-492.
Devare, S. G., Reddy, E. P., Law, J. D., Robbins, K. C., & Aaronson, S. A. (1983).
Nucleotide sequence o f the simian sarcoma virus genome: demonstration that
its acquired cellular sequences encode the transforming gene product p28sis.
Proc Natl Acad Sci U S A , 80(3), 731-735.
Domin, J., & Waterfield, M. D. (1997). Using structure to define the function o f
phosphoinositide 3-kinase family members. FEBS Lett, 410(1), 91-95.
Downes, C. P., Bennett, D., McConnachie, G., Leslie, N. R., Pass, I., MacPhee, C.,
Patel, L., & Gray, A. (2001). Antagonism o f PI 3-kinase-dependent signalling
pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans, 29(Pt
6), 846-851.
Dzitoyeva, S., Dimitrijevic, N., & Manev, H. (2001). Intra-abdominal injection o f
double-stranded RNA into anesthetized adult Drosophila triggers RNA
interference in the central nervous system. M ol Psychiatry, 6(6), 665-670.
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & TuschI, T.
(2001a). Duplexes o f 21-nucleotide RNAs mediate RNA interference in
cultured mammalian cells. Nature, 411(6836), 494-498.
Elbashir, S. M., Lendeckel, W., & TuschI, T. (2001b). RNA interference is mediated
by 21- and 22-nucleotide RNAs. Genes Dev, 15(2), 188-200.
Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., & TuschI, T. (2001c).
Functional anatomy o f siRNAs for mediating efficient RNAi in Drosophila
melanogaster embryo lysate. Embo J, 20(23), 6877-6888.
115

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Erpel, T., & Courtneidge, S. A. (1995). Src family protein tyrosine kinases and
cellular signal transduction pathways. Curr Opin Cell Biol, 7(2), 176-182.
Escobedo, J. A., Kaplan, D. R., Kavanaugh, W. M., Turck, C. W., & Williams, L. T.
(1991a). A phosphotidylinositol-3 kinase binds to platelet-derived growth
factor receptors through a specific receptor sequence containing
phosphotyrosine. Mol. Cell. Biol., 11, 1125-1132.
Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfay, D., Fried, V. A., &
Williams, L. T. (1991b). cDNA cloning o f a novel 85 kd protein that has SH2
domains and regulates binding o f PI3-kinase to the PDGF (3—receptor. Cell,
65, 75-82.
Factor, V., Oliver, A. L., Panta, G. R., Thorgeirsson, S. S., Sonenshein, G. E., &
Arsura, M. (2001). Roles o f Akt/PKB and IKK complex in constitutive
induction o f NF-kappaB in hepatocellular carcinomas o f transforming growth
factor alpha/c-myc transgenic mice. Hepatology, 34(1), 32-41.
Fambrough, D., McClure, K., Kazlauskas, A., & Lander, E. S. (1999). Diverse
signaling pathways activated by growth factor receptors induce broadly
overlapping, rather than independent, sets o f genes. Cell, 97(6), 727-741.
Fantl, W. J., Escobedo, J. A., Martin, G. A., Turck, C. W., del Rosario, M.,
McCormick, F., & Williams, L. T. (1992). Distinct phosphotyrosines on a
growth factor receptor bind specific molecules that mediate different
signalling pathways. Cell, 69, 413-423.
Finco, T., Westwick , J., Norris, J., Beg, A., Der, C., & Jr, B. A. (1997). Oncogenic
Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which
is required for cellular transformation. J. Biol. Chem., 272(39), 24113-24116.
Finco, T. S., & Baldwin, A. S. (1995). Mechanistic aspects o f NF-kB regulation: the
emerging role of phosphorylation and proteolysis. Immunity, 3, 263-272.
Finco, T. S., Westwick, J. K., Norris, J. L., Beg, A. A., Der, C. J., & Baldwin, A. S.,
Jr. (1997). Oncogenic Ha-Ras-induced signaling activates NF-kappaB
transcriptional activity, which is required for cellular transformation. J Biol
Chem, 272(39), 24113-24116.
Fire, A., Xu, S., Montgomery, M. K , Kostas, S. A., Driver, S. E., & Mello, C. C.
(1998). Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature, 391(6669), 806-811.

116

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Flynn, P., Wongdagger, M., Zavar, M., Dean, N. M., & Stokoe, D. (2000). Inhibition
o f PD K -l activity causes a reduction in cell proliferation and survival. Curr
Biol, 10(22), 1439-1442.
Fosslien, E. (2000). Molecular pathology o f cyclooxygenase-2 in neoplasia [In
Process Citation]. Ann Clin Lab Sci, 50(1), 3-21.
Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., FCazlauskas, A., Morrison, D. K.,
Kaplan, D. R., & Tsichlis, P. N. (1995). The protein kinase encoded by the
Akt proto-oncogene is a target o f the PDGF-activated phosphatidylinositol 3kinase. Cell, 81(5), 727-736.
Frevert, E. U ., & Kahn, B. B. (1997). Differential effects o f constitutively active
phosphatidylinositol 3-kinase on glucose transport, glycogen synthase
activity, and DNA synthesis in 3T3-L1 adipocytes. Mol Cell Biol, 17( 1), 190198.
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998). Phosphoinositide kinases.
Annu R ev Biochem, 67, 481-507.
Ganchi, P. A., Sun, S. C., Greene, W. C., & Ballard, D. W. (1992). I kappa B/MAD-3
masks the nuclear localization signal o f NF-kappa B p65 and requires the
transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol Biol
Cell, 5(12), 1339-1352.
Gilmore, T. D. (1999a). Multiple mutations contribute to the oncogenicity o f the
retroviral oncoprotein v-Rel. Oncogene, 18(49), 6925-6937.
Gilmore, T. D. (1999b). The Rel/NF-kappaB
introduction. Oncogene, 18(49), 6842-6844.

signal

transduction

pathway:

Golub, T. R., Barker, G. F., Lovett, M., & Gilliand, D. G. (1994). Fusion o f PDGF
receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia
with t(5;12) chromosomal translocation. Cell, 77, 307-316.
Goppelt-Struebe, M., Stroebel, M., & Hoppe, J. (1996). Regulation o f platelet-derived
growth factor isoform-mediated expression o f prostaglandin G/H synthase in
m esangial cells. Kidney Int., 50, 71-78.
Grimm, S., 8c Baeuerle, P. A. (1994). Failure o f the splicing variant p65 delta o f the
NF-kappa B subunit p65 to transform fibroblasts. Oncogene, 9(8), 2391-2398.
Grishok, A., Tabara, H., & Mello, C. C. (2000). Genetic requirements for inheritance
o f RNAi in C. elegans. Science, 287(5462), 2494-2497.
117

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Guo, Q., Wang, L. H., Ruan, K. H., & Kulmacz, R. J. (1996). Role o f Val509 in timedependent inhibition o f human prostaglandin H synthase-2 cyclooxygenase
activity by iso form-selective agents. JB io l Chem, 27/(32), 19134-19139.
Guo, S., & Kemphues, K. J. (1995). par-1, a gene required for establishing polarity in
C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically
distributed. Cell, 81(4), 611-620.
Gura, T. (2000). A silence that speaks volumes. Nature, 404(6780), 804-808.
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. J.
(1999). NF-kB controls growth and differentiation through transcriptional
regualtion o f cyclin D l. Mol. Cell. Biol., 19(8), 5785-5799.
Hamilton, A. J., & Baulcombe, D. C. (1999). A species o f small antisense RNA in
posttranscriptional gene silencing in plants. Science, 286(5441), 950-952.
Hammond, S. M., Caudy, A. A., & Hannon, G. J. (2001). Post-transcriptional gene
silencing by double-stranded RNA. Nat Rev Genet, 2(2), 110-119.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks o f cancer. Cell, 100(1), 5770.
Hartwig, J. H., Kung, S., Kovacsovics, T., Janmey, P. A., Cantley, L. C., Stossel, T.
P., & Toker, A. (1996). D3 phosphoinositides and outside-in integrin
signaling by glycoprotein Hb-IIIa mediate platelet actin assembly and
filopodial extension induced by phorbol 12-myristate 13-acetate. J Biol Chem,
271(51), 32986-32993.
Heissmeyer, V., Krappmann, D., Wulczyn, F. G., & Scheidereit, C. (1999). NFkappaB pl05 is a target o f IkappaB kinases and controls signal induction o f
Bcl-3-p50 complexes. Embo J, 75(17), 4766-4778.
Heldin, C.-H., Backstrom, G., Ostman, A., Hammacher, A., Ronnstrand, L., Rubin,
K., Nister, M., & Westermark, B. (1989). Binding o f different dimeric forms
o f PDGF to human fibroblasts: evidence for two separate receptor types.
EMBOJ., 7, 1387-1393.
Heldin, C. H., Ostman, A., & Ronnstrand, L. (1998). Signal transduction via plateletderived growth factor receptors. Biochim Biophys Acta, 1378(1), F79-113.
Heldin, C. H., 8c Westermark, B. (1999). Mechanism o f action and in vivo role of
platelet-derived growth factor. Physiol Rev, 79(4), 1283-1316.
118

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Heldin, N. E., Usuki, K.., Bergh, J., Westermark, B., & Heldin, C. H. (1993).
Differential expression o f platelet-derived endothelial cell growth
factor/thymidine phosphorylase in human lung carcinoma cell lines. Br J
Cancer, 68(4), 708-711.
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001). Biologic
sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
Oncogene, 20(42), 5991-6000.
Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., & Strauss, M.
(1999). NF-kB function in growth control: regulation o f cyclin D1 expression
and GO/Gl-to-S-phase transition. Molecular and Cellular Biology, 19(4),
2690-2698.
Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E., & Prydz, H. (2002).
Positional effects o f short interfering RNAs targeting the human coagulation
trigger Tissue Factor. Nucleic Acids Res, 30(8), 1757-1766.
Hsu, S., Huang, F., & Friedman, E. (1995). Platelet-derived growth factor-B increases
colon cancer cell growth in vivo by a paracrine effect. J. Cell. Phys., 165, 239245.
Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., & Williams, L. T. (1995). Rasdependent induction o f cellular responses by constitutively active
phosphatidylinositol-3 kinase. Science, 268, 100-102.
Huang, C., Ma, W. Y., Hanenberger, D., Cleary, M. P., Bowden, G. T., & Dong, Z.
(1997). Inhibition o f ultraviolet B-induced activator protein-1 (AP-1) activity
by aspirin in AP-l-luciferase transgenic mice. J Biol Chem, 272(42), 2632526331.
Hunter, C. P. (2000). Gene silencing: shrinking the black box o f RNAi. Curr Biol,
10(4), R137-140.
Hutvagner, G., & Zamore, P. D. (2002). RNAi: nature abhors a double-strand. Curr
Opin Genet Dev, 12(2), 225-232.
Jazayeri, A., McGee, J., Shimamura, T., Cross, S. B., & Bejcek, B. E. (2000). SHP-2
can suppress transformation induced by platelet-derived growth factor. Exp
Cell Res, 254(2), 197-203.

119

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Johnsson, A., Heldin, C. H., Wasteson, A., Westermark, B., Deuel, T. F., Huang, J.
S., Seeburg, P. H., Gray, A., Ullrich, A., Scrace, G., & et al. (1984). The c-sis
gene encodes a precursor o f the B chain o f platelet-derived growth factor.
EmboJ, 3(5), 921-928.
Kamat, A., & Carpenter, G. (1997). Phospholipase C -gam m al: regulation o f enzyme
function and role in growth factor-dependent signal transduction. Cytokine
Growth Factor Rev, 8(2), 109-117.
Kamath, R. S., Martinez-Campos, M., Zipperlen, P., Fraser, A. G., & Ahringer, J.
(2001). Effectiveness o f specific RNA-mediated interference through ingested
double-stranded RNA in Caenorhabditis elegans. Genome Biol, 2(1),
RESEARCH0002.
Karin, M., Cao, Y., Greten, F. R., & Li, Z. W. (2002). NF-kappaB in cancer: from
innocent bystander to major culprit. Nature Rev Cancer, 2(4), 301-310.
Karin, M., & Lin, A. (2002). NF-kappaB at the crossroads o f life and death. Nat
Immunol, 2(3), 221-227.
Kashishian, A., & Cooper, J. A. (1993). Phosphorylation sites at the C-terminus o f the
platelet-derived growth factor receptor bind phospholipase Cgl. Mol. Cell.
Biol., 49-57.
Kashishian, A., Kazlauskas, A., & Cooper, J. A. (1992). Phosphorylation sites in the
PDGF receptor with different specificities for binding GAP and PI3 kinase in
vivo .E M B O J., 11, 1373-1382.
Kazlauskas, A., Feng, G.-S., Pawson, T., & Valius, M. (1993). The 64-kDa protein
that associates with the platelet-derived growth factor receptor b subunit via
Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. Proc. Nat.
Acad. Sci., 90, 6939-6942.
Kazlauskas, A., Kashishian, A., Cooper, J. A., & Valius, M. (1992). GTPase
activating protein and phosphatidylinositol 3-kinase bind distinct regions o f
the platelet-derived growth factor receptor b subunit. Mol. Cell. Biol., 12,
2534-2544.
Kennerdell, J. R., & Carthew, R. W. (1998). Use o f dsRNA-mediated genetic
interference to demonstrate that frizzled and frizzled 2 act in the wingless
pathway. Cell, 95(7), 1017-1026.
Kennerdell, J. R., & Carthew, R. W. (2000). Heritable gene silencing in Drosophila
using double-stranded RNA. Nat Biotechnol, 75(8), 896-898.
120

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Kieran, M ., Blank, V., Logeat, F., Vandekerckhove, J., Lottspeich, F., Le Bail, O.,
Urban, M. B., Kourilsky, P., Baeuerle, P. A., & Israel, A. (1990). The DNA
binding subunit o f NF-kappa B is identical to factor KBFl and homologous to
the rel oncogene product. Cell, 62(5), 1007-1018.
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., lannarelli, P., O'Reilly, T.,
Buchdunger, E., Black, P. M., & Stiles, C. D. (2000). Intracranial inhibition of
platelet-derived growth factor-mediated glioblastoma cell growth by an orally
active kinase inhibitor o f the 2-phenyIaminopyrimidine class. Cancer Res,
<50(18), 5143-5150.
Kilk, A., Talpsepp, T., Vali, U., & Ustav, M. (1996). Bovine papillomavirus
oncoprotein E5 induces the NF kappa B activation through superoxide
radicals. Biochem Mol Biol Int, 40(4), 689-697.
Kim, L., & Wong, T. W. (1995). The cytoplasmic tyrosine kinase FER is associated
with the catenin-like substrate p p l2 0 and is activated by growth factors. Mol
Cell Biol, 75(8), 4553-4561.
Klinghoffer, R. A., & Kazlauskas, A. (1995). Identification o f a putative Syp
substrate, the PDGF b receptor. J. Biol. Chem., 270(38), 22208-22217.
Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M. A., &
W illiams, L. T. (1996). Membrane localization o f phosphatidylinositol 3kinase is sufficient to activate multiple signal-transducing kinase pathways.
M ol C ell Biol, 76(8), 4117-4127.
Kopp, E., & Ghosh, S. (1994). Inhibition o f NF-kB by sodium salicylate and aspirin.
Science, 265,956-959.
Korus, M., Mahon, G. M., Cheng, L., & Whitehead, I. P. (2002). p38 MAPKmediated activation o f NF-kappaB by the RhoGEF domain o f Bcr. Oncogene,
27(30), 4601-4612.
Kovacsovics, T. J., Bachelot, C., Toker, A., Vlahos, C. J., Duckworth, B., Cantley, L.
C., & Hartwig, J. H. (1995). Phosphoinositide 3-kinase inhibition spares actin
assem bly in activating platelets but reverses platelet aggregation. J Biol Chem,
270(19), 11358-11366.
Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S., Fukui, Y., Ui, M.,
Hazeki, O., & Katada, T. (1997). Heterodimeric phosphoinositide 3-kinase
consisting o f p85 and pi lObeta is synergistically activated by the betagamma
subunits o f G proteins and phosphotyrosyl peptide. J B iol Chem, 272(39),
24252-24256.

121

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Kypta, R. M., Goldberg, Y., Ulug, E. T., & Courtneidge, S. A. (1990). Association
between the PDGF receptor and members o f the src family o f tyrosine
kinases. Cell, 6 2 ,481-492.
Laemmli, U. 1C. (1970). Cleavage o f structural proteins during the assembly o f the
head o f bacteriophage T4. Nature, 227, 680-685.
LaRochelle, W. J., Jeffers, M., McDonald, W. F., Chillakuru, R. A., Giese, N. A.,
Lokker, N. A., Sullivan, C., Boldog, F. L., Yang, M., Vemet, C., Burgess, C.
E., Fernandes, E., Deegler, L. L., Rittman, B., Shimkets, J., Shimkets, R. A.,
Rothberg, J. M., & Lichenstein, H. S. (2001). PDGF-D, a new proteaseactivated growth factor. Nat Cell Biol, 3(5), 517-521.
Lemmon, M. A., Ferguson, K. M., & Schlessinger, J. (1996). PH domains: diverse
sequences with a common fold recruit signaling molecules to the cell surface.
Cell, 85(5), 621-624.
Li, D. M., & Sun, H. (1998). PTEN/MMAC1/TEP1 suppresses the tumorigenicity
and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad
Sci U S A , 95(26), 15406-15411.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis,
C., Rodgers, L., McCombie, R., Bigner, S. H., Giovane, B. C., Ittmann, M.,
Tyco, B., Hibshoosh, H., Wigler, M. H., & Parsons, R. (1997). PTEN, a
putative protein tyrosine phasphatase gene mutated in human brain, breast,,
and prostate cancer. Science, 275(5308), 1943-1947.
Li, J. J., Rhim, J. S., Schlegel, R., Vousden, K. H., & Colburn, N. H. (1998).
Expression o f dominant negative Jun inhibits elevated AP-1 and NF- kappaB
transactivation and suppresses anchorage independent growth o f HPV
immortalized human keratinocytes. Oncogene, 16(21), 2711-2721.
Li, J. J., Westergaard, C., Ghosh, P., & Colbum, N. H. (1997). Inhibitors o f both
nuclear factor-kappaB and activator protein-1 activation block the neoplastic
transformation response. Cancer Res, 57(16), 3569-3576.
Li, W., Hu, P., Skolnik, E. Y., Ullrich, A., & Schlessinger, J. (1992). The SH2 and
SH3 domain-containing Nek protein is oncogenic and a common target for
phosphorylation by different surface receptors. Mol. Cell. Biol., 12, 58245833.

122

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Li, W., Michieli, P., Maurizio, A., Lorenzi, M. V., Wu, Y., Wang, L.-H., Heidaran,
M. A., & Pierce, J. H. (1996). Expression o f an ATP Binding Mutant o f PKCdelta inhibits Sis-induced Transformation o f NIH3T3 Cells. Oncogene, 13,
731-737.
Li, W., Nishimura, R., Kashishian, A., Batzer, A. G., Kim, W. J. H., Cooper, J. A., &
Schlessinger, J. (1994). A new function for a phosphotyrosine phosphatase:
linking GRB2-SOS to a receptor tyrosine kinase. Mol. Cell. Biol., 14, 509517.
Li, X., Ponten, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Backstrom, G.,
Hellstrom, M., Bostrom, H., Li, H., Soriano, P., Betsholtz, C., Heldin, C. H.,
Alitalo, K., Ostman, A., & Eriksson, U. (2000). PDGF-C is a new proteaseactivated ligand for the PDGF alpha-receptor. Nat Cell Biol, 2(5), 302-309.
Liu, Z. G., Hsu, H., Goeddel, D. V., & Karin, M. (1996). Dissection o f TNF receptor
1 effector functions: JNK activation is not linked to apoptosis while NFkappaB activation prevents cell death. Cell, 87(3), 565-576.
Lochhead, P. A., Coghlan, M., Rice, S. Q., & Sutherland, C. (2001). Inhibition o f
GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and
phosphoenolypyruvate carboxykinase gene expression. Diabetes, 50(5), 937946.
Madrid, L. V., Wang, C. Y., Guttridge, D. C., Schottelius, A. J., Baldwin, A. S., Jr., &
Mayo, M. W. (2000). Akt suppresses apoptosis by stimulating the
transactivation potential o f the RelA/p65 subunit o f NF-kappaB. Mol Cell
Biol. 20(5), 1626-1638.
Manche, L., Green, S. R., Schmedt, C., & Mathews, M. B. (1992). Interactions
between double-stranded RNA regulators and the protein kinase DAI. Mol
Cell Biol, 72(11), 5238-5248.
Mancini, J. A., Vickers, P. J., O’Neill, G. P., Boily, C., Falgueyret, J. P., & Riendeau,
D. (1997). Altered sensitivity of aspirin-acetylated prostaglandin G/H
synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs. Mol
Pharmacol, 5/(1), 52-60.
Matoskova, B., Rorsman, F., Svensson, V., & Betsholtz, C. (1989). Alternative
splicing o f the platelet-derived growth factor A-chain transcript occurs in
normal as well as tum or cells and is conserved among mammalian species.
Mol Cell Biol, 9(7), 3148-3150.

123

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Matsumoto, T., Yokote, K., Take, A., Takemoto, M., Asaumi, S., Hashimoto, Y.,
M atsuda, M., Saito, Y., & Mori, S. (2000). Differential interaction o f Crkll
adaptor protein with platelet-derived growth factor alpha- and beta-receptors
is determined by its internal tyrosine phosphorylation. Biochem Biophys Res
Commun, 270(1), 28-33.
Mercola, D., Westwick, J., Rundell, A. Y., Adamson, E. D., & Edwards, S. A. (1988).
Analysis o f a transformed cell line using antisense c-fos RNA. Gene, 72(1-2),
253-265.
Minks, M. A., West, D. K., Benvin, S., & Baglioni, C. (1979). Structural
requirements o f double-stranded RNA for the activation o f 2\5'-oligo(A)
polymerase and protein kinase o f interferon-treated HeLa cells. J Biol Chem,
254(20), 10180-10183.
Mori, S., Roonstrand, L., Yokote, K., Engstrom, A., Courtnidge, S. A., ClaessonWelsh, L., & Heldin, C.-H. (1993). Identification o f two juxtamembrane
autophosphorylation sites in the PDGF b-receptor; involvement in the
interaction with Src family tyrosine kinases. EM BOJ., 12, 2257-2264.
Murata, H., Kawano, S., Tsuji, S., Tsuji, M., Sawaoka, H., Kimura, Y., Shiozaki, H.,
& Hori, M. (1999). Cyclooxygenase-2 overexpression enhances lymphatic
invasion and metastasis in human gastric carcinoma. Am J Gastroenterol,
94(2), 451-455.
Murphy, K., Shimamura, T., & Bejcek, B. E. (2001). Use o f fluorescently labeled
DNA and a scanner for electrophoretic mobility shift assays. Biotechniques,
30(3), 504-506, 508.
Nakanishi, S., Kakita, S., Takahashi, I., Kawahara, K., Tsukuda, E., Sano, T.,
Yamada, K., Yoshida, M., Kase, H., Matsuda, Y., & et al. (1992).
W ortmannin, a microbial product inhibitor o f myosin light chain kinase. J
Biol Chem, 267(4), 2157-2163.
Newton, A. C. (1997). Regulation o f protein kinase C. Curr Opin Cell Biol, 9(2),
161-167.
Nishimura, R., Li, W., Kashishian, A., Mondino, A., Zhou, M., Cooper, J., &
Schlessinger, J. (1993). Two signaling molecules share a phosphotyrosinecontaining binding site in the platelet-derived growth factor receptor. Mol.
Cell. Biol., 13, 6889-6896.

124

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Nister, M., Claesson-Welch, L., Eriksson, A., Heldin, C.-H., & Westermark, B.
(1991). Differential expression o f platelet-derived growth factor receptors in
human malignant glioma cell lines. J. Biol. Chem., 266, 16755-16763.
Novak, U., Mui, A., Miyajima, A., & Paradiso, L. (1996). Formation o f STAT5containing DNA binding complexes in response to colony-stimulating factor-1
and platelet-derived growth factor. J B io l Chem, 27/(31), 18350-18354.
Nykanen, A., Haley, B., & Zamore, P. D. (2001). ATP requirements and small
interfering RNA structure in the RNA interference pathway. Cell, 107(3),
309-321.
Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O., & Ui, M. (1994a). Essential role
of phosphatidylinositol 3-kinase in insulin-induced glucose transport and
antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J
Biol Chem, 269(5), 3568-3573.
Okada, T., Sakuma, L., Fukui, Y., Hazeki, O., & Ui, M. (1994b). Blockage o f
chemotactic peptide-induced stimulation o f neutrophils by wortmannin as a
result o f selective inhibition o f phosphatidylinositol 3-kinase. J Biol Chem,
269(5), 3563-3567.
Olashaw, N. E., Kowalik, T. F., Huang, E. S., & Pledger, W. J. (1992). Induction o f
NF-kappa B-like activity by platelet-derived growth factor in mouse
fibroblasts. M ol Biol Cell, 2(10), 1131-1139.
Olivera, A., Edsall, L., Poulton, S., Kazlauskas, A., & Spiegel, S. (1999). Plateletderived growth factor-induced activation o f sphingosine kinase requires
phosphorylation o f the PDGF receptor tyrosine residue responsible for
binding o f PLCgamma. FasebJ, 73(12), 1593-1600.
Ostman, A., Thyberg, J., Westermark, B., & Heldin, C. H. (1992). PDGF-AA and
PDGF-BB biosynthesis: proprotein processing in the Golgi complex and
lysosomal degradation o f PDGF-BB retained intracellularly. J Cell Biol,
118(3), 509-519.
Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D.
B. (1999). NF-kB activation by tumor necrosis factor requires the Akt-serinethreonine kinase. Nature, 401, 82-85.
Pap, M., & Cooper, G. M. (1998). Role o f glycogen synthase kinase-3 in the
phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem,
273(32), 19929-19932.
125

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Paul, C. P., Good, P. D., Winer, I., & Engelke, D. R. (2002). Effective expression o f
small interfering RNA in human cells. Nat Biotechnol, 20(5), 505-508.
Paulose, M., Bennett, B. L., Manning, A. M., & Essani, K. (1998). Selective
inhibition o f TNF-alpha induced cell adhesion molecule gene expression by
tanapox virus. Microb Pathog, 25(1), 33-41.
Perkins, N. D., Schmid, R. M., Duckett, C. S., Leung, K., Rice, N. R., & Nabel, G. J.
(1992). Distinct combinations o f NF-kappa B subunits determine the
specificity o f transcriptional activation. Proc Natl Acad Sci U S A , 89(5),
1529-1533.
Persson, C., Engstrom, U., Mowbray, S. L., & Ostman, A. (2002). Primary sequence
determinants responsible for site-selective dephosphorylation o f the PDGF
beta-receptor by the receptor-like protein tyrosine phosphatase D E P-l. FEBS
Lett, 577(1-3), 27-31.
Petti, L., Nilson, L. A., & DiMaio, D. (1991). Activation o f the platelet-derived
growth factor receptor by the bovine papillomavirus E5 transforming protein.
EmboJ, 10(A), 845-855.
Petti, L. M., Irusta, P. M., & DiMaio, D. (1998). Oncogenic activation o f the PDGF
beta receptor by the transmembrane domain o f p!85neu*. Oncogene, 16(1),
843-851.
Petti, L. M., Reddy, V., Smith, S. O., & DiMaio, D. (1997). Identification o f amino
acids in the transmembrane and juxtamembrane domains o f the plateletderived growth factor receptor required for productive interaction with the
bovine papillomavirus E5 protein. J Virol, 7/(10), 7318-7327.
Peyrollier, K., Hajduch, E., Blair, A. S., Hyde, R., & Hundal, H. S. (2000). L-leucine
availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and
glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the
involvement o f the mammalian target o f rapamycin (mTOR) pathway in the
L-leucine-induced up-regulation o f system A amino acid transport. Biochem J,
350 Pt 2, 361-368.
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E.
(2001). Her-2/neu overexpression induces NF-kappaB via a P13-kinase/Akt
pathway involving calpain-mediated degradation o f IkappaB-alpha that can be
inhibited by the tumor suppressor PTEN. Oncogene, 20(11), 1287-1299.

126

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Pollack, I. F., Randall, M. S., Kristofik, M. P., Kelly, R. H., Selker, R. G., &
Vertosick, F. T. (1990). Response o f malignant glioma cell lines to epidermal
growth factor and platelet-derived growth factor in a serum-free medium. J
Neurosurg, 75(1), 106-112.
Prayson, R. A., Castilla, E. A., Vogelbaum, M. A., & Barnett, G. H. (2002).
Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in
glioblastoma multiforme. Ann Diagn Pathol, 6(3), 148-153.
Rameh, L. E., Arvidsson, A., Carraway, K. L., 3rd, Couvillon, A. D., Rathbun, G.,
Crompton, A., VanRenterghem, B., Czech, M. P., Ravichandran, K. S.,
Burakoff, S. J., Wang, D. S., Chen, C. S., & Cantley, L. C. (1997a). A
comparative analysis o f the phosphoinositide binding specificity o f pleckstrin
homology domains. J B io l Chem, 272(35), 22059-22066.
Rameh, L. E., Chen, C. S., & Cantley, L. C. (1995). Phosphatidylinositol (3,4,5)P3
interacts with SH2 domains and modulates PI 3-kinase association with
tyrosine-phosphorylated proteins. Cell, 33(5), 821-830.
Rameh, L. E., Tolias, K. F., Duckworth, B. C., & Cantley, L. C. (1997b). A new
pathway for synthesis o f phosphatidylinositol-4,5-bisphosphate. Mature,
390(6656), 192-196.
Rapoport, I., Miyazaki, M., Boll, W., Duckworth, B., Cantley, L. C., Shoelson, S., &
Kirchhausen, T. (1997). Regulatory interactions in the recognition o f
endocytic sorting signals by AP-2 complexes. Embo J, 16(9), 2240-2250.
Ratner, L., Joesphs, S. F., Jarrett, R., Reitz, M. S., Jr., & Wong-Staal, F. (1985).
Nucleotide sequence o f transforming human c-sis cDNA clones with
homology to platelet-derived growth factor. Nuc. Acids Res., 13, 5007-5018.
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., & Baldwin, A. S. J.
(1998). A requirement for NF-kB activation in Bcr-Abl-mediated
transformation. Genes & Development, 12,968-981.
Rice, N., & Ernst, M. K. (1993). In vivo control of NF-kB activation by IkBa. EMBO
J., 12(12), 4685-4695.
Riese, D. J., 2nd, & DiMaio, D. (1995). An intact PDGF signaling pathway is
required for efficient growth transformation o f mouse C l 27 cells by the
bovine papillomavirus E5 protein. Oncogene, 10(7), 1431-1439.

127

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Roche, S., Downward, J., Raynal, P., & Courtneidge, S. A. (1998). A function for
phosphatidylinositol 3-kinase beta (p85alpha-pll0beta) in fibroblasts during
mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated
signal transduction. M ol Cell Biol, 75(12), 7119-7129.
Roche, S., McGlade, J., Jones, M., Gish, G. D., Pawson, T., & Courtneidge, S. A.
(1996). Requirement o f phospholipase C gamma, the tyrosine phosphatase
Syp and the adaptor proteins She and Nek for PDGF-induced DNA synthesis:
evidence for the existence o f Ras-dependent and Ras-independent pathways.
Embo J, 75(18), 4940-4948.
Rodriguez-Viciana, P., Wame, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry,
M. J., Waterfield, M. D., & Downward, J. (1994). Phosphatidylinositol-3-OH
kinase as a direct target o f Ras. Nature, 570(6490), 527-532.
Romashkova, J. A., & Makarov, S. S. (1999). NF-kB is a target o f AKT in antiapoptotic PDGF signaling. NAture, 401, 85-90.
Ronnstrand, L., Mori, S., Arridsson, A. K., Eriksson, A., Wemstedt, C., Heilman, U.,
Claesson-Welsh, L., & Heldin, C. H. (1992). Identification o f two C-terminal
autophosphorylation sites in the PDGF b-receptor:involvement in the
interaction with phospholipase C -g . EM BOJ., 11, 3911-3919.
Rorsman, F., Bywater, M., Knott, T. J., Scott, J., & Betsholtz, C. (1988). Structural
characterization o f the human platelet-derived growth factor A-chain cDNA
and gene: alternative exon usage predicts two different precursor proteins.
M ol Cell Biol, 8(2), 571-577.
Rosenberg, L., Louik, C., & Shapiro, S. (1998). Nonsteroidal antiinflammatory drug
use and reduced risk o f large bowel carcinoma. Cancer, 52(12), 2326-2333.
Ross, T. S., Bernard, O. A., Berger, R., & Gilliland, D. G. (1998). Fusion of
Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor
(PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;qll.2).
Blood, 91(12), 4419-4426.
Roth, G. J., Machuga, E. T., & Ozols, J. (1983). Isolation and covalent structure of
the aspirin-modified, active-site region o f prostaglandin synthetase.
Biochemistry, 22(20), 4672-4675.
Rozengurt, E., Sinnett-Smith, J., & Taylor-Papadimitriou, J. (1985). Production o f
PDGF-Iike growth factor by breast cancer cell lines. Int. J. Cancer, 36, 247252.
128

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Rubio, I., Rodriguez-Viciana, P., Downward, J., & Wetzker, R. (1997). Interaction o f
Ras with phosphoinositide 3-kinase gamma. Biochem J, 326 ( Pt 3), 891-895.
Sanchez-Margalet, V., Goldfine, I. D., Vlahos, C. J., & Sung, C. K. (1994). Role o f
phosphatidylinositol-3-kinase in insulin receptor signaling: studies with
inhibitor, LY294002. Biochem Biophys Res Commun, 204(2), 446-452.
Schilling, D., Reid, I. J., Hujer, A., Morgan, D., Demoll, E., Bummer, P.,
Fenstermaker, R. A., & Kaetzel, D. M. (1998). Loop III region o f plateletderived growth factor (PDGF) B-chain mediates binding to PDGF receptors
and heparin. Biochem J, 333 (P t 3), 637-644.
Schlessinger, J. (1993). How receptor tyrosine kinases activate Ras. Trends Biochem
Sci, 75(8), 273-275.
Schmid, A., Schindelholz, B., & Zinn, K. (2002). Combinatorial RNAi: a method for
evaluating the functions o f gene families in Drosophila. Trends Neurosci,
25(2), 71-74.
Shamah, S. M., Stiles, C. D., & Guha, A. (1993). Dominant negative mutant o f the
platelet derived growth factor reverts the transformed phenotype o f human
astrocytoma cells. Mol. Cell. Biol., 13, 7203-7212.
Shao, R., Karunagaran, D., Zhou, B. P., Li, K., Lo, S. S., Deng, J., Chiao, P., & Hung,
M. C. (1997). Inhibition of nuclear factor-kappaB activity is involved in E1Amediated sensitization o f radiation-induced apoptosis. J Biol Chem, 272(52),
32739-32742.
Shao, R., Tsai, E. M., Wei, K., von Lindem, R., Chen, Y. H., Makino, K., & Hung,
M. C. (2001). El A Inhibition o f Radiation-induced NF-kappaB Activity
through Suppression o f IKK Activity and IkappaB Degradation, Independent
o f Akt Activation. Cancer Res, 61(20), 7413-7416.
Sharp, P. A. (2001). RNA interference-2001. Genes Dev, 15(5), 485-490.
Sharp, P. A., & Zamore, P. D. (2000). Molecular biology. RNA interference. Science,
287(5462), 2431-2433.
Shi, Z. Q., Lu, W., & Feng, G. S. (1998). The Shp-2 tyrosine phosphatase has
opposite effects in mediating the activation o f extracellular signal-regulated
and c-Jun NH2-terminal mitogen-activated protein kinases. J Biol Chem,
273(9), 4904-4908.

129

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Shier, W. T., & Durkin, J. P. (1982). Role o f stimulation o f arachidonic acid release
in the proliferative response o f 3T3 mouse fibroblasts to platelet-derived
growth factor. J. Cell. Physiol., 112, 171-181.
Shimamura, T., Hsu, T. C., Colburn, N. H., & Bejcek, B. E. (2002). Activation o f NFkappaB Is Required for PDGF-B Chain to Transform NIH3T3 Cells. Exp Cell
Res, 274(1), 157-167.
Shin, I., Bakin, A. V., Rodeck, U., Brunet, A., & Arteaga, C. L. (2001). Transforming
growth factor beta enhances epithelial cell survival via Akt-dependent
regulation o f FKHRL1. M ol Biol Cell, 12(\ 1), 3328-3339.
Siddhanta, U., Mcllroy, J., Shah, A., Zhang, Y., & Backer, J. M. (1998). Distinct
roles for the pllOalpha and hVPS34 phosphatidylinositol 3'-kinases in
vesicular trafficking, regulation o f the actin cytoskeleton, and mitogenesis. J
Cell Biol, 143(6), 1647-1659.
Sliva, D., Rizzo, M. T., & English, D. (2002). Phosphatidylinositol 3-kinase and NFkappaB regulate motility o f invasive MDA-MB-231 human breast cancer cells
by the secretion o f urokinase-type plasminogen activator. J Biol Chem,
277(5), 3150-3157.
Smalley, W. E., & DuBois, R. N. (1997). Colorectal cancer and nonsteroidal anti
inflammatory drugs. Adv Pharmacol, 39, 1-20.
Smith, S. O., Smith, C. S., & Bormann, B. J. (1996). Strong hydrogen bonding
interactions involving a buried glutamic acid in the transmembrane sequence
o f the neu/erbB-2 receptor. Nat Struct Biol, 3(3), 252-258.
Sohn, R. H., Chen, J., Koblan, K. S., Bray, P. F., & Goldschmidt-Clermont, P. J.
(1995). Localization o f a binding site for phosphatidylinositol 4,5bisphosphate on human profilin. J Biol Chem, 270(36), 21114-21120.
Somwar, R., Sweeney, G., Ramlal, T., & Klip, A. (1998). Stimulation o f glucose and
amino acid transport and activation o f the insulin signaling pathways by
insulin lispro in L6 skeletal muscle cells. Clin Ther, 20(1), 125-140.
Songyang, Z., Sholeson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G.,
King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R.
B., Fajardo, J. E., Chou, M. M., Hanafiisa, H., Schaffhausen, B., & Cantley, L.
C. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell,
72, 767-778.

130

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Sorensen, S. D., Linseman, D. A., McEwen, E. L., Heacock, A. M., & Fisher, S. K.
(1998). A role for a wortmannin-sensitive phosphatidylinositol-4-kinase in the
endocytosis o f muscarinic cholinergic receptors. Mol Pharmacol, 55(5), 827836.
Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Stemweis, P. C., & Hawkins,
P. T. (1994). A novel phosphoinositide 3 kinase activity in myeloid-derived
cells is activated by G protein beta gamma subunits. Cell, 77(1), 83-93.
Stephens, L. R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell,
J., Smrcka, A. S., Thelen, M., Cadwallader, K., Tempst, P., & Hawkins, P. T.
(1997). The G beta gamma sensitivity o f a PI3K is dependent upon a tightly
associated adaptor, plO l. Cell, 59(1), 105-114.
Stephens, L. R., Hughes, K. T., & Irvine, R. F. (1991). Pathway o f
phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils.
Nature, 351(6321), 33-39.
Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F.,
Holmes, A. B., McCormick, F., & Hawkins, P. T. (1997). Dual role o f
phosphatidylinositol-3,4,5-trisphosphate in the activation o f protein kinase B.
Science, 277(5325), 567-570.
Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D.,
Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Numberg, B., & et al. (1995).
Cloning and characterization o f a G protein-activated human
phosphoinositide-3 kinase. Science, 269(5224), 690-693.
Strawn, L. M., Mann, E., Elliger, S. S., Chu, L. M., Germain, L. L., Neiderfellner, G.,
Ullrich, A., & Shawver, L. K. (1994). Inhibition o f glioma cell growth by a
truncated platelet-derived growth factor-b receptor. Journal o f Biological
Chemistry, 269(33), 21215-21222.
Suzuki, H., Terauchi, Y., Fujiwara, M., Aizawa, S., Yazaki, Y., Kadowaki, T., &
Koyasu, S. (1999). Xid-like immunodeficiency in mice with disruption o f the
p85alpha subunit o f phosphoinositide 3-kinase. Science, 255(5400), 390-392.
Tabara, H., Grishok, A., & Mello, C. C. (1998). RNAi in C. elegans: soaking in the
genome sequence. Science, 252(5388), 430-431.
Tang, E. D., Nunez, G., Barr, F. G., & Guan, K. L. (1999). Negative regulation o f the
forkhead transcription factor FKHR by Akt. J Biol Chem, 274(24), 1674116746.
131

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Tang, X., & Downes, C. P. (1997). Purification and characterization o f Gbetagammaresponsive phosphoinositide 3-kinases from pig platelet cytosol. J Biol Chem,
272(22), 14193-14199.
Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno, A., Inukai, K.,
Asano, T., Kaburagi, Y., Ueki, K., Nakajima, H., Hanafusa, T., Matsuzawa,
Y., Sekihara, H., Yin, Y., Barrett, J. C., Oda, H., Ishikawa, T., Akanuma, Y.,
Komuro, I., Suzuki, M., Yamamura, K.., Kodama, T., Suzuki, H., Kadowaki,
T., & et al. (1999). Increased insulin sensitivity and hypoglycaemia in mice
lacking the p85 alpha subunit o f phosphoinositide 3-kinase. Mat Genet, 21(2),
230-235.
Timmons, L., Court, D. L., & Fire, A. (2001). Ingestion o f bacterially expressed
dsRNAs can produce specific and potent genetic interference in
Caenorhabditis elegans. Gene, 263(1-2), 103-112.
Timmons, L., & Fire, A. (1998). Specific interference by ingested dsRNA. Nature,
595(6705), 854.
Toker, A., Bachelot, C., Chen, C. S., Falck, J. R., Hartwig, J. H., Cantley, L. C., &
Kovacsovics, T. J. (1995). Phosphorylation o f the platelet p47 phosphoprotein
is mediated by the lipid products o f phosphoinositide 3-kinase. J Biol Chem,
270(49), 29525-29531.
Touhara, K., Inglese, J., Pitcher, J. A., Shaw, G., & Lefkowitz, R. J. (1994). Binding
o f G protein beta gamma-subunits to pleckstrin homology domains. J Biol
Chem. 269(14), 10217-10220.
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998).
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
[published erratum appears in Cell 1998 Jul 24;94(2):following 271], Cell,
93(5), 705-716.
Uddin, S., Kottegoda, S., Stigger, D., Platanias, L. C., & Wickrema, A. (2000).
Activation o f the Akt/FKHRLl pathway mediates the antiapoptotic effects o f
erythropoietin in primary human erythroid progenitors. Biochem Biophys Res
Commun, 275(1), 16-19.
Ui, M., Okada, T., Hazeki, K., & Hazeki, O. (1995). W ortmannin as a unique probe
for an intracellular signalling protein, phosphoinositide 3-kinase. Trends
Biochem Sci. 20(8), 303-307.
Urban, M. B., & Baeuerle, P. A. (1990). The 65-kD subunit o f NF-kappa B is a
receptor for I kappa B and a modulator o f DNA-binding specificity. Genes
Dev, 4(11), 1975-1984.
132

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Valgeirsdottir, S., Paukku, K., Silvennoinen, O., Heldin, C. H., & Claesson-Welsh, L.
(1998). Activation o f Stat5 by platelet-derived growth factor (PDGF) is
dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane
and kinase insert domains. Oncogene. 16(4), 505-515.
Valius, M., Bazenet, C., & Kazlauskas, A. (1993). Tyrosines 1021 and 1009 are
phosphorylation sites in the carboxy terminus o f the platelet-derived growth
factor b subunit and are required for binding o f phospholipase Cg and a 64kilodalton protein, respectively. Mol. Cell. Biol., 13, 7266-7277.
Valius, M., Secrist, J. P., & Kazlauskas, A. (1995). The GTPase-activating protein o f
Ras suppresses platelet-derived growth factor b receptor signaling by
silencing phospholipase C -gl. Mol. Cell. Biol., 15(6), 3058-3071.
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996).
Suppression o f TNF-alpha-induced apoptosis by NF-kappaB. Science,
274(5288), 787-789.
van der Geer, P., Henkemeyer, M., Jacks, T., & Pawson, T. (1997). Aberrant Ras
regulation and reduced pl90 tyrosine phosphorylation in cells lacking p i 20Gap. Mol Cell Biol, 17(4), 1840-1847.
Vanhaesebroeck, B., Jones, G. E., Allen, W. E., Zicha, D., Hooshmand-Rad, R.,
Sawyer, C., Wells, C., Waterfield, M. D., & Ridley, A. J. (1999). Distinct
PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat
Cell Biol, 7(1), 69-71.
Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., & Waterfield, M. D. (1997a).
Phosphoinositide 3-kinases: a conserved family o f signal transducers. Trends
Biochem Sci, 22(1), 267-272.
Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R., Wame, P. H., Zvelebil, M.
J., Higashi, K., Volinia, S., Downward, J., & Waterfield, M. D. (1997b).
PllOdelta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad
Sci U S A . 94(9), 4330-4335.
Vassbotn, F. S., Ostman, A., Langeland, N., Holmsen, H., Westermark, B., Heldin,
C.-H., & Nister, M. (1994). Activated platelet-derived growth factor autocrine
pathway drives the transformed phenotype o f a human glioblastoma cell line.
J. Cell. Phys., 158, 381-389.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S.
(1995). Rel/NF-kappa B/I kappa B family: intimate tales o f association and
dissociation. Genes Dev, 9(22), 2723-2735.
133

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Vignais, M. L., Sadowski, H. B., Watling, D., Rogers, N. C., & Gilman, M. (1996).
Platelet-derived growth factor induces phosphorylation o f multiple JAK
family kinases and ST AT proteins. Mol Cell Biol, 16(4), 1759-1769.
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994). A specific inhibitor
of
phosphatidylinositol
3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-lbenzopyran-4-one (LY294002). J Biol Chem, 269(1), 5241-5248.
Von Willebrand, M., Jascur, T., Bonnefoy-Berard, N., Yano, H., Altman, A.,
Matsuda, Y., & Mustelin, T. (1996). Inhibition o f Phosphatidylinositol 3Kinase Blocks T Cell Antigen Receptor/CD3-Induced Activation of the
Mitogen-Activated Kinase Erk2. European Journal o f Biochemistry, 235,
828-835.
Wahl, M. I., Olashaw, N. E., Nishibe, S., Rhee, S. G., Pledger, W. J., & Carpenter, G.
(1989). Platelet-derived growth factor induces rapid and sustained tyrosine
phosphorylation o f phospholipase C-gamma in quiescent BALB/c 3T3 cells.
M ol Cell Biol, 9(1), 2934-2943.
Wang, C. Y., Cusack, J. C., Jr., Liu, R., & Baldwin, A. S., Jr. (1999a). Control of
inducible chemoresistance: enhanced anti-tumor therapy through increased
apoptosis by inhibition o f NF-kappaB. Nat Med, 5(4), 412-417.
Wang, C. Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S., Jr. (1999b). NFkappaB induces expression o f the Bcl-2 homologue A l/Bfl-1 to preferentially
suppress chemotherapy-induced apoptosis. Mol Cell Biol, 19(9), 5923-5929.
Wang, Y. Z., Wharton, W., Garcia, R., Kraker, A., Jove, R., & Pledger, W. J. (2000).
Activation o f Stat3 preassembled with platelet-derived growth factor beta
receptors requires Src kinase activity. Oncogene, 79(17), 2075-2085.
Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., & Greene, M. I. (1989). A point
mutation in the neu oncogene mimics ligand induction o f receptor
aggregation. Nature, 339(6221), 230-231.
Whiteside, S. T., Ernst, M. K , LeBail, O., Laurent-Winter, C., Rice, N., & Israel, A.
(1995). N- and C-terminal sequences control degradation o f MAD3/I kappa B
alpha in response to inducers o f NF-kappa B activity. M ol Cell Biol, 75(10),
5339-5345.
Williams, C., Shattuck-Brandt, R. L., & DuBois, R. N. (1999). The role o f COX-2 in
intestinal cancer [In Process Citation], Ann N Y Acad Sci, 889, 72-83.

134

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Wong, K., & Cantley, L. C. (1994). Cloning and characterization o f a human
phosphatidylinositol 4-kinase. J Biol Chem, 269(46), 28878-28884.
Worby, C. A., Simonson-Leff, N., & Dixon, J. E. (2001). RNA interference o f gene
expression (RNAi) in cultured Drosophila cells. Sci STKE, 2001(95), PL1.
Yamada, K., Goncalves, E., Kahn, C. R., & Shoelson, S. E. (1992). Substitution o f
the insulin receptor transmembrane domain with the c- neu/erbB2
transmembrane domain constitutively activates the insulin receptor kinase in
vitro. J Biol Chem, 267(18), 12452-12461.
Yamamoto, H., Crow, M., Cheng, L., Lakatta, E., & Kinsella, J. (1996). PDGF
receptor-to-nucleus signaling o f p91 (STAT1 alpha) transcription factor in rat
smooth muscle cells. Exp Cell Res, 222(1), 125-130.
Yang, D., Buchholz, F., Huang, Z., Goga, A., Chen, C. Y., Brodsky, F. M., & Bishop,
J. M. (2002). Short RNA duplexes produced by hydrolysis with Escherichia
coli RNase HI mediate effective RNA interference in mammalian cells. Proc
Natl Acad Sci U S A , 99(15), 9942-9947.
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998). The anti-inflammtory agents
aspirin and salicylate inhibit the activity o f IkBkinase-b. Nature, 396, 77-80.
Yokote, K., Margolis, B., Heldin, C.-H., & Claesson-Welsh, L. (1996). Grb7 is a
downstream signaling component o f platelet-derived growth factor a and b
receptors./. Biol. Chem., 27/(48), 30942-30949.
Yokote, K., Mori, S., Hansen, K., McGlade, J., Pawson, T., Heldin, C.-H., &
Claesson-Welsh, L. (1994). Direct interaction between She and the plateletderived growth factorb receptor./. Biol. Chem., 269, 15337-15343.
Yokouchi, M., Wakioka, T., Sakamoto, H., Yasukawa, H., Ohtsuka, S., Sasaki, A.,
Ohtsubo, M., Valius, M., Inoue, A., Komiya, S., & Yoshimura, A. (1999).
APS, an adaptor protein containing PH and SH2 domains, is associated with
the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis.
Oncogene, 18(3), 759-767.
Yu, F. X., Sun, H. Q., Janmey, P. A., & Yin, H. L. (1992). Identification o f a
polyphosphoinositide-binding sequence in an actin monomer-binding domain
o f gelsolin. J Biol Chem, 267(21), 14616-14621.
Zamore, P. D., TuschI, T., Sharp, P. A., & Bartel, D. P. (2000). RNAi: double
stranded RNA directs the ATP-dependent cleavage o f mRNA at 21 to 23
nucleotide intervals. Cell, 70/(1), 25-33.
135

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Zhang, X., Loijens, J. C., Boronenkov, I. V., Parker, G. J., Norris, F. A., Chen, J.,
Thum, O., Prestwich, G. D., Majerus, P. W., & Anderson, R. A. (1997).
Phosphatidylinositol-4-phosphate 5-kinase isozymes catalyze the synthesis of
3-phosphate-containing phosphatidylinositol signaling molecules. J Biol
Chem. 272(28), 17756-17761.

136

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

